Detection of porcine umbilical cord matrix stem cells in the intestine and other organs after oral and intraperitoneal administration to allogeneic recipients by Packthongsuk, Kreeson
  
DETECTION OF PORCINE UMBILICAL CORD MATRIX STEM CELLS IN THE 
INTESTINE AND OTHER ORGANS AFTER ORAL AND INTRAPERITONEAL 
ADMINISTRATION TO ALLOGENEIC RECIPIENTS 
 
 
by 
 
 
KREESON PACKTHONGSUK 
 
 
 
D.V.M., Kasetsart University, Bangkok, Thailand, 2002 
M.Sc., Kasetsart University, Bangkok, Thailand, 2002 
 
 
 
AN ABSTRACT OF A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 
DOCTOR OF PHILOSOPHY 
 
 
 
Department of Animal Sciences and Industry 
College of Agriculture 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2013 
 
 
  
 
Abstract 
Umbilical cords matrix stem cells (UCs) have been characterized most thoroughly in 
humans (HUCs) and are considered to have great promise for regenerative medicine and cell-
based therapy. Although UCs were first identified in pigs the description of porcine UCs (PUCs) 
is limited. Here we reported some standard mesenchymal stem cell characteristics for PUCs. 
Development of knowledge about PUCs is useful because the pig is a valuable biomedical model 
for humans and the species is an important human food source. PUCs were isolated from 
Wharton’s jelly using an explant technique. They attached on the plastic and showed fibroblast-
like morphology. Immunophenotype analysis showed they are positive for CD44, CD90 and 
CD105 and negative for CD31, CD45 and SLA-DR. Under specific in vitro conditions, PUCs 
were differentiated to adipocytes, chondrocytes and osteocytes. The growth curve of PUCs 
exhibited a lag phase, log phase and doubling time of 24, 60 and 13.8 hour respectively. 
Engraftment potential of allogeneic PUCs administered orally and intraperitoneally (IP) 
was evaluated. Newborn, 1-day, 1-week, 2-week and 3-week old pigs were administered a dose 
of fluorescently labeled PUCs (1.1x10
7
 cells/kg body weight) and their tissue incorporation were 
evaluated using confocal microscopy with confirmation by PCR to detect SRY gene, the Y-
chromosome gene of male PUCs in female recipients. One week after PUCs administration, they 
were found mostly in the gastrointestinal tract and abdominal organs after either oral or 
intraperitoneal transplantation. The intestinal mucosa layer around the base of villi and intestinal 
crypts was the main location. PUCs were also detected in thoracic organs, muscle and bone 
marrow. Additionally, PKH26-labeled fibroblasts labeled were detected in recipient intestine 1 
week after IP injection. Donor cells were not found in blood at one week post transplantation. 
When recipients were sacrificed at 6 h after IP injection PKH26-labeled PUCs were found 
mostly in omentum and diaphragm by PCR. It is likely these are the primary sites for donor cells 
in the peritoneal cavity to enter the circulation. Fluorescent in situ hybridization (FISH), using an 
SRY probe and PCR, demonstrated the PUCs isolated from recipient intestines by enzymatic 
digestion. Therefore, transplanted PUCs were recovered from the intestinal mucosa and were 
viable and able to proliferate in vitro. 
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Abstract 
Umbilical cords matrix stem cells (UCs) have been characterized most thoroughly in 
humans (HUCs) and are considered to have great promise for regenerative medicine and cell-
based therapy. Although UCs were first identified in pigs the description of porcine UCs (PUCs) 
is limited. Here we reported some standard mesenchymal stem cell characteristics for PUCs. 
Development of knowledge about PUCs is useful because the pig is a valuable biomedical model 
for humans and the species is an important human food source. PUCs were isolated from 
Wharton’s jelly using an explant technique. They attached on the plastic and showed fibroblast-
like morphology. Immunophenotype analysis showed they are positive for CD44, CD90 and 
CD105 and negative for CD31, CD45 and SLA-DR. Under specific in vitro conditions, PUCs 
were differentiated to adipocytes, chondrocytes and osteocytes. The growth curve of PUCs 
exhibited a lag phase, log phase and doubling time of 24, 60 and 13.8 hour respectively. 
Engraftment potential of allogeneic PUCs administered orally and intraperitoneally (IP) 
was evaluated. Newborn, 1-day, 1-week, 2-week and 3-week old pigs were administered a dose 
of fluorescently labeled PUCs (1.1x10
7
 cells/kg body weight) and their tissue incorporation were 
evaluated using confocal microscopy with confirmation by PCR to detect SRY gene, the Y-
chromosome gene of male PUCs in female recipients. One week after PUCs administration, they 
were found mostly in the gastrointestinal tract and abdominal organs after either oral or 
intraperitoneal transplantation. The intestinal mucosa layer around the base of villi and intestinal 
crypts was the main location. PUCs were also detected in thoracic organs, muscle and bone 
marrow. Additionally, PKH26-labeled fibroblasts labeled were detected in recipient intestine 1 
week after IP injection. Donor cells were not found in blood at one week post transplantation. 
When recipients were sacrificed at 6 h after IP injection PKH26-labeled PUCs were found 
mostly in omentum and diaphragm by PCR. It is likely these are the primary sites for donor cells 
in the peritoneal cavity to enter the circulation. Fluorescent in situ hybridization (FISH), using an 
SRY probe and PCR, demonstrated the PUCs isolated from recipient intestines by enzymatic 
digestion. Therefore, transplanted PUCs were recovered from the intestinal mucosa and were 
viable and able to proliferate in vitro.
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Chapter 1 - Literature Review 
 Introduction 
Mesenchymal stem cells (MSCs) are multipotent cells that have the potential to 
differentiate into various mesodermal lineages (Bianco et al., 2001). In addition, the ability to 
transplant across major histocompatibility complex (MHC) barriers without the need for immune 
suppression makes MSCs an attractive source for cell therapy. Multiple studies have shown that 
MSCs suppress the proliferation of alloreactive T cells (Bartholomew et al., 2002), inhibit the 
differentiation and maturation of dendritic cells (Jiang et al., 2005), and decrease the production 
of inflammatory cytokines by immune cells (Aggarwal and Pittenger, 2005). Immunosuppressive 
properties of MSCs have been used in treatments for acute refractory graft-versus host disease 
(GVHD) following allogeneic hematopoietic stem cells transplantation (Le Blanc et al., 2004). 
Although bone marrow (BM) represents the main source of MSCs for both experimental 
and clinical studies, the use of BM-MSCs is not always acceptable because of the invasive 
harvesting procedure. Furthermore, the number of BM-MSCs has been reported to decline with 
increasing age (Stenderup et al., 2003). Recent studies have indicated that MSCs can be isolated 
from a variety of tissues, including adipose tissue (De Girolamo et al., 2008), umbilical cord 
(Wang et al., 2004; Lu et al., 2006), placenta (Barlow et al., 2008) and amnion (Bilic et al., 
2008). Tissue from amnion, placenta, Wharton’s jelly and umbilical cord represent promising 
sources of MSCs due to abundant and easily obtained by non-invasive procedures.  
The umbilical cord (UC) is an essential part of the conceptus and contributes to fetal 
development by providing the blood flow between placenta and fetus. In most species, including 
pigs and humans, the UC contains two arteries and one vein which are surrounded by a bulk of 
mucous connective tissue called Wharton’s jelly (Corrao et al., 2013). In addition, the UC may 
contain the remnants of yolk sac (omphalomesenteric duct) and allantois (urachus). The UC 
vessels are formed by extraembryonic mesoderm and connect the embryo to the extraembryonic 
blood circulation. The cord is covered by epithelium derived from the amnion sac. The UC 
contains a reservoir of mesenchymal stromal cell populations that are in the sub-amnion layer, 
Wharton’s jelly and the perivascular region (Troyer and Weiss, 2008).  
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Fine structural, immuno-histochemical and functional analysis performed in vitro show 
significant differences in the number and nature of cells among subamniotic, intervascular and 
perivascular regions. However, they all express similar surface markers suggesting that they are 
all of mesenchymal stem cell (also called mesenchymal stromal cell: MSC) origin (Nanaev et al., 
1997; Karahuseyinoglu et al., 2007). Wharton’s jelly is a mucus connective tissue component of 
the umbilical cord matrix stem cells (UMCs) in vivo environment and is considered to contribute 
to the distinct features of UMCs including high colony forming unit-fibroblast (CFU-F) 
capability, high proliferative potential, short population doubling time and long life in vitro 
(Guillot et al., 2007). Wharton’s jelly contains growth factors including insulin-like growth 
factor I (IGF-1), basic fibroblast growth factor (bFGF), transforming growth factor β (TGF-β) 
and epidermal growth factor (EGF) (Sobolewski et al., 2005). Wharton’s jelly extracts contain 
extracellular matrix protein and growth factors that in a reconstructed microenvironment for 
culturing MSCs resulted in a delay of MSCs replication senescence during in vitro long term 
culture (Hao et al., 2013).  
An important role of the Wharton’s jelly is to prevent compression, torsion and bending 
of the umbilical vessels which provide the oxygen and nutrients and remove carbon dioxide and 
waste products of developing fetus. Wharton’s jelly is characterized by a loose aggregation of 
cells surrounded by extracellular matrix. It contains laminin, abundant collagen (type I, III and 
VI) and glycosaminoglycans (GAGs). Hyaluronic acid and heparin sulphate proteoglycan 
constitute 70% of the total GAGs (Bankowski et al., 1996).  
During embryogenesis, the totipotent primordial germ cells and hematopoietic stem cells 
migrate from yolk sac through the region that becomes the umbilical cord on their way to 
populate target tissues in the embryo and fetus (Mitchell et al., 2003). MSC precursors have been 
found in the yolk sac (Wang et al., 2008a) and these cells might be trapped in the connective 
tissue matrix of the developing umbilical cord as they migrate along with HSCs precursors from 
blood islands located in yolk sac to the aorta-gonad-mesonephros region during early 
embryogenesis (Ueno et al., 2010).  
UMCs can be collected from Wharton’s jelly pre- or perinatally. In humans, the UC are 
normally discarded after birth and there are no ethical concerns for UMCs harvest. Isolation of 
UMCs from cords postnatally is non-invasive and without pain, in contrast, to adult stem cell 
(ASC) isolation. Moreover, the numbers of isolated MSCs from adult tissues such as a bone 
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marrow significantly decreases with age and infirmity (Rao and Mattson, 2001) and there is a 
potential risk of viral contamination during the isolation of MSCs from bone marrow (Romanov 
et al., 2003).  
Unlike ASCs, UMCs possess characteristics of embryonic stem cells in that they 
consistently express ESC markers and pluripotency markers including alkaline phosphatase, 
Nanog, Oct-4, Sox-2, Tra-1-60, Tra-1-81, stage specific embryonic antigen-1 (SSEA-1), SSEA-
4, Hoechst 33342 dye exclusion and even form embryoid bodies in vitro (Carlin et al., 2006; 
Weiss et al., 2006; Fong et al., 2007; La Rocca et al., 2009; Nekanti et al., 2010a). They also do 
not form teratomas after in vivo transplantation, a significant drawback of ESCs (Mitjavila-
Garcia et al., 2005).  
The most common methods to isolate MSCs from Wharton’s jelly are based on the use of 
explant-culture or enzymatic digestion techniques. Fresh umbilical cord is transported 
immediately to the lab and the umbilical cord vessels are removed. Wharton’s jelly is excised 
and minced to small pieces before being plated directly for the explant method or digested using 
a cocktail of proteolytic enzymes ( for example collagenase/hyaluronidase/trypsin). The 
advantage of enzymatic digestion is that it reduces the contamination with other cell types such 
as red blood cells and endothelial cells (Troyer and Weiss, 2008). Higher rates of expression of 
MSC markers was observed in cells isolated from Wharton’s jelly by the explant-culture method 
and, also, these cells had a higher proliferation rate compared to cells derived by enzymatic 
digestion methods (collagenase/hyaluronidase/trypsin, collagenase/trypsin and trypsin) 
(Salehinejad et al., 2012).  
The collagenase/trypsin method of cell isolation yields higher cell numbers than other 
enzymatic digestion methods such as collagenase/hyaluronidase/trypsin and trypsin. These 
isolated cells expressed a greater amount of the pluripotent markers as C-kit and Oct-4 than cells 
isolated from explant and collagenase/hyaluronidase/trypsin methods (Salehinejad et al., 2012). 
Yoon et al (2013) also reported advantages of explant culture of Wharton’s jelly for acquiring 
both UMCs and the secreted natural cytokine bFGF (Yoon et al., 2013). A simple and rapid 
method for isolation UMCs from the whole UC is by injection of enzymatic solution into the tied 
cord. The direct delivery of enzymatic solution into Wharton jelly was reported to provide a high 
yield of isolated cells (1.5-2 x 10
6
/cm) with MSCs properties (Montanucci et al., 2011). 
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 Characterization of UMCs 
Cells isolated from Wharton’s jelly possess the MSCs properties proposed by the 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy 
(ISCT) (Dominici et al., 2006). The three minimal criteria to define MSCs: are adherence to 
plastic culture ware, specific surface antigen expression, and multipotent differentiation 
potential. Flow cytometric analysis of MSCs should demonstrate surface antigen expression of 
CD90, CD105 and CD73. Furthermore, these cells should show low expression of CD34, CD45, 
CD14 or CD11b, CD79a or CD19 and HLA class II proteins. Other markers such as CD140b, 
SSEA-4 and a neural ganglioside GD2 may also be prospective markers for MSCs to distinguish 
MSCs from all other cells within marrow (Gang et al., 2007; Martinez et al., 2007; Roobrouck et 
al., 2011). Finally, these cells must demonstrate the ability to differentiate along osteogenic, 
adipogenic and chondrogenic lineages under standard in vitro differentiating conditions. These 
criteria were developed for human MSCs and human UMCs possess plastic adherence, can be 
differentiated into chondrogenic, adipogenic and osteogenic lineages and possess expression of 
the follow cell markers: CD105+ (endoglin, SH2), CD73+ (SH3), CD90+ (Thy-1), HLA-A,B,C+ 
(MHC class I). They are CD34-, CD45-, HLA-DR- (MHC class II) (Christodoulou et al., 2013). 
UMCs express the mesodermal markers vimentin, alpha smooth muscle actin (α-SMA) and 
CD117 (the receptor for stem cell factor (SCF)); moreover, a subset of UMCs express nestin, the 
intermediate filament of neuroectodermal cellular lineage (Fu et al., 2006; La Rocca et al., 2009). 
Recently UMCs have been reported to express the mRNA and proteins for the transcription 
factors GATA-4, GATA-5 and GATA-6 (La Rocca et al., 2009) that are involved in 
development pathways of mesoderm and endoderm-derived organs. Moreover, UMCs isolated 
by non-enzymatic methods express a subset of epithelial cytokeratins (CK); CK8, CK18 and 
CK19 (Moll et al., 2008; La Rocca et al., 2009).  
Although human UMCs present a phenotypic profile mostly resembling human BM-
MSCs, some differences exist in the two cell populations. UMCs expressed CD49b (integrin-α2) 
but BM-MSCs lacked this surface marker. The expression level of CD73 and HLA-I were lower 
in UMCs than BM-MSCs (Friedman et al., 2007). Moreover, CD106 (VCAM-1) was expressed 
weakly in BM-MSCs but UMCs do not have this surface marker (Martin-Rendon et al., 2008). 
Wharton’s jelly of UC is a rich source of MSCs, with 6-8x105 isolated cells/cm of human 
umbilical cord length reported (Tsagias et al., 2011). CFU-F analysis showed higher frequency 
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of CFU-F of MSCs derived from Wharton’s jelly compared to bone marrow and umbilical cord 
blood (UCB) MSCs (Karahuseyinoglu et al., 2007; Lu et al., 2008). Oxygen concentration and 
plating density affect the proliferation of UMCs with relative hypoxia and low cell plating 
density enhancing CFU-F frequency and cumulative population doubling without an impact on 
cell surface marker expression and differentiation potential (Nekanti et al., 2010b; Lopez et al., 
2011).  
Compared to BM-MSCs, UMCs are reported to have a relatively higher proliferation 
potential, higher telomerase activity, shorter population doubling time and longer time to 
senescence without loss of stem cell potency. UMCs also did not show contact-inhibited cell 
growth like BM-MSCs (Baksh et al., 2007). UMCs have a steeper log phase and short doubling 
time. The mean doubling time of early passage UMCs has been reported to be 24 hours and 
remained almost constant up to passage 10 (Lu et al., 2006). In contrast, early BM-MSCs and 
adipose tissue-derived MSCs (ADCs) had a longer mean doubling time of 40 and 45 hours 
respectively (Peng et al., 2008).  
Besides the higher proliferative activity of UMCs, they showed no sign of senescence 
over several passages. Conconi et al (2006) cultured UMCs over 30 doublings in 16 serial 
passages and found no variation in cell morphology or senescence (Conconi et al., 2006). Also, 
porcine UMSCs were cultured in vitro for more than 80 doublings with no decrease of 
proliferative capacity (Mitchell et al., 2003). Mean population doubling (PD) per passage of 
UMCs and ADCs has been reported as 2.8 and 0.8 respectively (Christodoulou et al., 2013). 
Karahuseyinoglu et al (2007) were able to expand UMCs more than 300 fold over 7 passages 
(Karahuseyinoglu et al., 2007) and Lund et al (2007) reported that UMCs could be expanded to 
more than 10
15
 cells (Lund et al., 2007). UMCs had a normal karyotype after in vitro culture (P1-
P60), indicating that cell culture may not alter chromosomal organization (Cardoso et al., 2012).  
Telomeres are the repetitive DNA sequence localized at the end of all chromosomes to 
protect the end of the chromosome from deterioration or from fusion with neighboring 
chromosomes. Cell division results in shortening of telomeres and when they get too short, the 
cell no longer can divide and becomes "senescent" or dies (Blackburn, 2001). Telomerase is a 
complex of telomeric RNA and telomerase reverse transcriptase (TERT) that functions by adding 
telomeric repeats onto chromosome ends to extend the possible cell divisions. This enzyme 
prevents the replication-dependent loss of telomeres and cellular senescence in highly 
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proliferative cells (Blasco, 2005). MSCs with high proliferation potential contain telomere 
lengths around 10-15 kb longer than somatic cell with telomere lengths 5-8 kb (Cheng et al., 
2008a). UMCs have telomeres around 9 kb similar to dental papilla-derived MSCs and ADCs 
but longer than cancer cell lines and somatic cells. Relative telomerase activity (RTA) of UMCs 
was higher than ADCs but lower than cancer cell lines (Jeon et al., 2011). UMCs with long 
telomeres and high levels of telomerase activity are consistent with high proliferation in long-
term culture. 
 Differentiation potential of UMCs 
Adipogenic, Osteogenic, and Chondrogenic differentiation 
UMCs can be induced to differentiate into mesodermal and non-mesodermal lineages. 
Human UMCs could differentiate to osteoblasts, adipocytes and chondrocytes under specific in 
vitro conditions (Wang et al., 2004; Karahuseyinoglu et al., 2007; Chen et al., 2009; Huang et al., 
2012), therefore fulfilling one of the minimal criteria proposed by ISCT for MSCs. Under 
adipogenic differentiation conditions with supplements of 1-methyl-3- isobutylxanthine (IBMX), 
dexamethasone, insulin and indomethacin, UMCs differentiate into adipocytes. However, lipid 
accumulation staining with Oil Red O takes longer to develop in UMCs and the adipocytes are 
less mature than those derived from BM-MSCs (Karahuseyinoglu et al., 2007; Troyer and Weiss, 
2008; Shetty et al., 2010). UMCs displayed chondrogenic potential in vitro in micromass culture 
with induction by dexamethasone, ascorbic acid, ITS (insulin, transferrin and selenium), TGF-β, 
IGF-1 and FGF. The histological analysis revealed production of cartilage-specific highly 
sulphated proteoglycans and type II collagen stained specifically with Alcian blue dye (Augello 
et al., 2010). Up-regulated expression of Sox9, a key transcription factor for chondrogenesis, has 
been reported after inducing with TGF-β (Kawakami et al., 2006; Lorda-Diez et al., 2009).  
UMCs embedded in a scaffold of a collagen (type I) hydrogel underwent chondrogenesis 
after culturing with chondrogenic differentiation medium (Chen et al., 2013). UMCs seeded on a 
polyglycolic acid (PGA) scaffold and cultured with chodrogenic medium differentiated into 
chondrocytes. They outperformed temporomandibular joint (TMJ) condylar cartilage cells for 
proliferation and synthesis of collagen type I, and type II, and glucoaminoglycans. UMCs may 
therefore be an attractive alternative to condylar cartilage cells for TMJ tissue engineering 
applications (Bailey et al., 2007). Incubation monolayers of UMCs with dexamethasone, 
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ascorbic acid and β-glycerol phosphate showed osteogenic differentiation based on alkaline 
phosphatase activity, increase of collagen (type I) production, calcium incorporation into the 
extracellular matrix and up-regulation of the osteogenic related genes osteopontin and 
osteocalcin (Lovati et al., 2011).  
UMCs seeded in high density in 3D scaffolds of polyglycolic acid (PGA) differentiated 
into osteocytes after culturing in osteogenic differentiation medium. This provides the foundation 
for future applications of stem cells-based bone tissue engineering (Wang et al., 2010). In 
addition, UMCs have been shown to possess weaker osteogenic (Hsieh et al., 2010) and 
chondrogenic (Wang et al., 2009a; Melania et al., 2011) potential as compared to BM-MSCs. 
UMCs genetically engineered to overexpress Osx a transcription factor essential for osteoblast 
differentiation showed more osteogenic differentiation in both in vivo and in vitro (Wang et al., 
2012). Gene expression profiles of UMCs exposed to hypoxia reveal up-regulation of early 
mesodermal and endothelial genes including DESMIN, CD34 and ACTC, suggesting that in 
vitro culturing of WJ-MSCs under hypoxic conditions leads to adoption of a 
mesodermal/endothelial fate (Nekanti et al., 2010b). 
 Neural differentiation 
UMCs have been shown to express the morphological and biochemical properties of 
neural cells when exposed to appropriate differentiation media. Basic FGF, EGF, retinoic acid, 
valproic acid, insulin, hydrocortisone, β-mercaptoethanol (BME), butyrated hydroxyanisole 
(BHA) and dimethyl sulfoxide (DMSO) were added for inducing neurogenesis (Fu et al., 2006). 
Neural-like cells derived from UMCs cultured in neurogenic differentiation medium expressed 
neuronal precursors and the mature neuron specific proteins nestin, β-III tubulin, microtubule-
associated protein 2 (MAP-2), neurofilament-M, Neu-N and neuron specific enolase (NSE) (Ma 
et al., 2005; Karahuseyinoglu et al., 2007). Glial fibrillary acidic protein (GFAP) and 2’,3’-
Cyclic-nucleotide 3’-phosphodiesterase (CNPase), markers for glial cells, astrocytes and 
oligodendrocytes were expressed in UMCs induced by neurogenic differentiation medium 
(Mitchell et al., 2003). Neuronal conditioned medium containing sonic hedgehog and FGF8 
induced in vitro differentiation of UMCs into dopaminergic neurons containing tyrosine 
hydroxylase (TH), indicating UMCs may be therapeutic for Parkinson’s disease (Fu et al., 2006).  
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Undifferentiated UMCs derived from preterm birth displayed the neural progenitor cell 
markers Nestin and Musashi-1 and the mature neural markers MAP-2, GFAP and myelin basic 
protein. They could be successful induced into neural progenitors similar to UMCs derived from 
term birth controls (Messerli et al., 2013). It has been suggested that UMCs may be more primed 
for neuronal differentiation than BM-MSCs because they expressed higher levels of the neuronal 
associated genes NESTIN, GFAP and SEM3A in a non-differentiated state (Nekanti et al., 
2010a). Under identical in vitro induction conditions, earlier generation of neurospheres was 
noted from UMCs compared to BM-MSCs. UMC derived neurospheres were able to 
differentiate to neuronal cells when culturing with brain-derived neurotrophic factor (BDNF). 
They also promoted functional recovery after spinal cord transection (Hermann et al., 2004; 
Zhang et al., 2009a). UMC-derived neurospheres express nestin, Sox2 and Pax6 transcription 
factors and self-renew and differentiate to neuron/glial-like cells. Evaluation of the secretome 
profile suggests that UMCs secrete more neurotrophic factors, consistent with UMCs ability to 
make neural progenitors with higher efficiency than BM-MSCs and ADCs (Balasubramanian et 
al., 2013).  
UMCs migrate and survive in brain injury sites and differentiate in vivo into neurons and 
glia (Weiss et al., 2003; Jomura et al., 2007). Matsuse et al (2010) reported high efficiency 
differentiation of human UMCs to Schwann cells after incubation in neurogenic differentiation 
medium comprised of beta-mercaptoethanol, retinoic acid, bFGF, PDGF and the heregulin-A1-
EGF domain and forskolin. The function of Schawann cells derived from UMCs is comparable 
to that of native human Schwann cells in vivo (Matsuse et al., 2010). Growth factor-based 
methods enable the differentiation of UMCs toward immature neuronal-like cells that retain their 
immunomodulatory and anti-oxitative activities (Li et al., 2012). 
 Endodermal-lineage differentiation 
 Beta cells 
Recent studies suggest that UMCs can also differentiate into endodermal lineages. After 
culturing in low-glucose medium supplemented with nicotinamide, UMCs were differentiated 
into mature islet-like cell clusters possessing insulin-producing ability in vitro and in vivo. 
Differentiated UMCs expressed insulin and other pancreatic beta-cell-related genes including 
Pdx1, Hlxb9, Nkx2.2, Nkx6.1, and Glut-2. The hyperglycemia and glucose intolerance in 
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streptozotocin-induced diabetic recipients was significantly alleviated after transplantation of 
these islet-like cell clusters (Chao et al., 2008). UMCs had higher pancreatic differentiation 
potential than BM-MSCs and may therefore be more suitable for pancreatic tissue engineering in 
the treatment of type I diabetes than BM-MSCs (Wu et al., 2009b). Genetic reprogramming by 
transfection of neurogenic differentiation 1 gene (NeuroD1) into UMCs together with in vitro 
culture in beta-mercaptoethanol (BME) and nicotinamide differentiated UMCs to insulin 
producing cells that expressed the pancreatic β-cell marker, PDX-1 (Wang et al., 2011). 
 Hepatic cells 
Non-differentiated UMCs constitutively expressed markers of the hepatic lineage 
including albumin, alpha-fetoprotein, cytokeratin-19, conexin-32 and dipeptidyl peptidase IV as 
well as weaker hepatocyte-specific functions were observed when compared to adult hepatocytes 
(Zhang et al., 2012b). UMCs cultured in hepatic differentiation medium showed up-regulation of 
hepatic markers, stored glycogen, produced urea and exhibited an inducible CYP 3A4 activity. 
(Campard et al., 2008; Anzalone et al., 2010). One step hepatic induction of human UMCs using 
hepatocyte growth factor (HGF) and fibroblast growth factor-4 (FGF-4) has been reported. The 
hepatocyte-like cells expressed the hepatocyte-specific markers albumin (ALB), human alpha-
fetoprotein (AFP) and cytokeratin 18 (CK-18), stored glycogen and took up low-density 
lipoprotein (LDL) (Zhang et al., 2009b). Functional hepatocyte-like cells derived from induced 
UMCs retained low immunogenicity in vitro and they incorporated into the liver parenchyma 
after transplantation into damaged liver (Zhao et al., 2009). 
 Cardiac muscle 
UMCs also have cardiac muscle differentiation potential. They exhibit myocardial 
morphology and express the myocardial markers cardiac troponin I, connexin-43 and desmin 
after being treated with 5-azacytidine (Wang et al., 2004). 5-Azacytidine induces cardiac 
differentiation of human UMCs by activating extracellular regulated kinase (ERK) (Qian et al., 
2012). UCMs induced by 5-azacytidine and bFGF and platelet-derived growth factor (PDGF) 
expressed in vitro cardiac myosin and cardiac troponin T (cTnT). UMCs transplanted into 
infarcted areas incorporated into foci of neovascularization, differentiated into cardiomyocyte-
like cells and improved the cardiac function (Wu et al., 2009a). Cardiomyocyte conditioned 
medium supplemented with a bioactive lipid metabolite, sphingosine 1-phosohate (S1P) induce 
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differentiation of UMCs to functional cardiomyocyte-like cells with cardiomyocyte-like action 
potential and voltage gated currents (Zhao et al., 2011b).  
UMCs are induced toward skeletal muscle cells when they are cultured in myogenic 
differentiation medium. The differentiated cells expressed myogenic factor-5 (Myf-5) and the 
myogenic regulatory factor MyoD. UMCs not only differentiate in vivo towards the myogenic 
lineage, but also to contribute to the muscle regenerative process (Conconi et al., 2006). Cell 
reprogramming by transfection of the transcription factor MyoD, the master regulator of skeletal 
muscle differentiation, into UMCs induced myogenic differentiation. Transfected UMCs formed 
multinucleated myofibers in vitro, and they exhibited the functional markers of fusion machinery 
including M-cadherin, β-catenin, and muscle cell-specific structural proteins including desmin, 
α-actinin, dystrophin, myosin heavy chain, and myoglobin (Kocaefe et al., 2010). 
 Endothelial cells 
Mature endothelial cells are highly effective for promoting vascularization to improve 
blood transfusion, cell viability and survival of engrafted tissues after transplantation. However, 
they have limited proliferation potential (Levenberg et al., 2005). UMCs may be an alternative 
cell source for neovascularization because they differentiate into endothelial cells after culturing 
in vitro with vascular endothelial growth factor (VEGF) and bFGF. The UMC-derived 
endothelial-like cells incorporated acetylated low-density lipoprotein and expressed the 
endothelial-specific proteins PECAM and CD34. 
 After transplantation into an ischemic mouse model, UMCs grew from the injection 
point and differentiated into endothelial cells in a lesioned hind limb (Wu et al., 2007a). UMCs 
had higher proliferative potential, higher expression of endothelial-specific markers after 
induction and significantly greater total tubule length, diameter, and area in angiogenesis assays 
than those of differentiated BM-MSCs (Chen et al., 2009). UMCs transplanted into wire-injured 
femoral arteries in mice play an important role in re-establishing endothelial integrity by 
inhibiting neointimal hyperplasia (Wang et al., 2009b).  
Under hypoxic conditions, UMCs support angiogenesis both in vitro and in vivo. They 
secrete membrane microvesicles (MVs) promoting proliferation of endothelial cells and the 
formation of capillary networks. This significantly improved blood flow recovery in ischemia 
(Zhang et al., 2012a). 
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 UMCs in co-culture 
 Hematopoietic stem cells (HSCs) 
MSCs facilitate hematopoietic stem cell growth in vitro and in vivo by constitutive 
secretion of hematopoietic cytokines including IL-6, IL-7, IL-8, IL-11, IL-14, IL-15, 
macrophage colony-stimulating factor (M-CSF) and stem cell factor (SCF) (Kim et al., 2004; Li 
et al., 2007). UMCs express stromal supporting properties that are similar to BM-MSCs and they 
express mRNA for SCF, leukemia inhibitor factor (LIF), M-CSF, Flt3-ligand, IL-6, VEGF, 
stromal-derived factor-1 (SDF-1) granulocyte macrophage colony-stimulating factor (GM-CSF) 
and granulocyte colony-stimulating factors (G-CSF) (Lu et al., 2006).  
Umbilical cord blood (UCB) transplantation has several advantages over bone marrow 
(BM) transplantation. Collection of UCB is a non-invasiveness procedure and is technically 
easier than BM collection. There is reduced risk of infections, and a greater HLA disparity is 
tolerated for UCB grafts with a decreased frequency of acute or chronic graft versus host disease 
(GVHD) as compared to BM grafts (Mayani and Lansdorp, 1998; Gluckman, 2000). Bakhshi et 
al (2008) reported that human UMCs are similar to BM-MSCs for supporting the growth of 
CD34+ cord blood cells in long term ex vivo culture (Bakhshi et al., 2008). UMCs produce more 
G-CSF, GM-CSF, hepatocyte growth factor (HGF), LIF, IL-1a, IL-6, IL-8 and IL-11 than BM-
MSCs in culture. UMCs augmented hematopoietic colony formation when co-cultured with UCB 
mononuclear cells in vitro and promoted engraftment of human UCB cells or CD34+ selected 
cells in mice when co-transplanted (Friedman et al., 2007). UMCs also increased homing and 
improved migration efficiency of UCB CD34+ cells to bone marrow and spleen in vivo by 
expressing the homing molecules CD49e, CD 31, CD62L and CD11a (Hao et al., 2009). 
 Embryonic stem cells (ESCs)  
Hiroyama et al (2008) reported that human UMC feeder cells could maintain the lineage 
and hematopoietic differentiations of ESCs more than 3 months. ESCs express the pluripotent 
markers alkaline phosphatase, SSEA-4 and Oct-3/4 after they are co-cultured with irradiated 
human UMCs (Hiroyama et al., 2008). 
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 Immuno-modulation 
UMCs possess various immunoregulatory properties that make them appealing 
candidates for cell based therapies. UMCs inhibit the splenocyte proliferation response to 
concanavalin A stimulation and proliferation of stimulated T cells in a two way mixed 
lymphocyte reaction (MLR). UMCs block non-stimulated splenocyte proliferation and stimulate 
T-cell proliferation in a one-way MLR. Mitogen-induced splenocyte proliferation is inhibited by 
UMCs in co-culture assay but there was no effect in non-stimulated splenocytes (Zhou et al., 
2011).  
UMCs have been observed to produce VEGF and IL-6 and these could be involved in 
modulation but expression of co-stimulatory surface antigens like CD40, CD80 and CD86 was 
not detected (Weiss et al., 2008; Manochantr et al., 2013). Comparative analysis of 
immunomodulatory properties and immunesuppressive effect of MSCs derived from bone 
marrow, adipose tissue, UCB and Wharton’s jelly showed that there were no significant 
differences in the level of secreted factors in non-stimulated MSCs from the different sources 
and they have similar effects on phytohemagglutinin-induced T-cell proliferation (Yoo et al., 
2009).  
UMCs suppressed mitogen-induced T-cell proliferation and the suppressive effect of 
IFN-ɣ and/or TNF-α produced by activated T-cells was correlated to the ability of the factor to 
stimulate production of  indoleamine 2,3 dioxgenase (IDO) by UMCs, which, in turn, inhibited 
T-cell proliferation (Yoo et al., 2009). Human leukocyte antigen (HLA) class I molecule, HLA-
G, and IDO have been shown to play crucial immunosuppressive roles in fetal-maternal 
tolerance. HLA-G inhibits natural killer and T cell function by high-affinity interaction with 
inhibitory receptors, and IDO acts by depleting the surrounding microenvironment of the 
essential amino acid tryptophan, thus inhibiting T cell proliferation (Mellor et al., 2002). B7-H1 
(programmed death ligand-1) one of the members of B7 family molecules is able to bind to 
programmed cell death receptor expressed on T-cells. Activation of B7-H1 expressed on murine 
BM-MSCs inhibited lymphocyte proliferation (Sheng et al., 2008). The study of Tipnis et al. 
(2010) has shown that human UMCs induced by IFN-ɣ up-regulated IDO and B7-H1 and these 
molecules were actively involved in suppressing T-cell proliferation.  
UMCs express low amounts of HLA-ABC (MHC class I) and do not express HLA-DR 
(MHC class II) enabling them to escape immune recognition. In comparison to BM-MSCs 
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derived from aged donors, UMCs expressed significantly lower levels of HLA class I and exhibit 
significantly higher intracellular concentrations of the immunosuppressive molecule HLA-G 
(Deuse et al., 2011). Cho et al (2008) found that porcine UMCs could be activated to express 
MHC class II and increase MHC class I with IFN-ɣ stimulation in vitro. UMCs could induce an 
immune response when they were injected in an inflamed region or injected repeatedly in the 
same region or stimulated with IFN-ɣ prior to injection. However a single injection of MHC-
mismatched unactivated UMCs did not induce a detected immune response (Cho et al., 2008). 
Deuse et al (2011) reported that IFN-ɣ at doses below 50 ng/ml up-regulated HLA-DR and HLA 
class I expression, therefore increasing UMCs immunogeneticity. However, higher doses of IFN-
ɣ enhanced the UMCs immunosuppressive phenotype by down-regulating HLA-DR expression 
and further increasing IDO. Also, IFN-ɣ treatment induced tolerogenicity by increasing 
intracellular HLA-G expression, TGF-β and IL-10 release as well as stimulation of IDO 
production (Deuse et al., 2011).  
UMCs and their culture supernatant inhibit the proliferation of phytohemagglutinin-
stimulated human peripheral blood lymphocytes and mouse splenocytes. They also suppressed 
secretion of transforming growth factor-β1 and interferon-γ by human peripheral blood 
lymphocytes. Zhou et al (2011) suggested that the immunomodulatory effect of UMCs may be 
related to direct cell contact and the secreted soluble factors HGF, prostaglandin E2 (PGE2), 
TGF-β and IDO (Zhou et al., 2011). Immune suppression exerted by UCMs is mediated by 
cycloxygenase (COX) 1 and COX2 enzymes that regulate PGE2 synthesis whereas HGF did not 
seem to be implicated (Chen et al., 2010).  
UMCs stimulated by inflammatory cytokines displayed potent immunosuppressive 
effects on lymphocyte responses in a dose-dependent manner that prevented lymphocyte 
activation and suppressed T-cell proliferation. CD4+ and CD8+ T subpopulations were equally 
targeted for proliferation inhibition regardless of the stimulus used to activate T-cells. 
Furthermore, UMC-mediated inhibitory effects were higher than with BM-MSCs (Najar et al., 
2010).  
UMCs were found to inhibit B cell proliferation, differentiation and antibody production 
in vitro. Soluble factors secreted from UMCs, at least in part, might down-regulate Blimp-1 and 
up-regulate PAX-5, two master regulators of B-cell differentiation. UMCs inhibited Akt and p38 
MAPK phosphorylation that signal transduction pathways are involved in regulation of B-cell 
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proliferation and differentiation (Che et al., 2012). UMCs have immunomodulatory effects on 
antigen presenting cells (APCs) by inhibiting differentiation, maturation and endocytosis of 
monocyte-derived dendritic cells through secreted factors without direct cell contacts. CD 14+ 
monocytes were down-regulated for CD80, CD86, CD83 and HLA-DR the key markers in 
mature dendritic cells, when they were co-cultured in induction medium containing IL-4 and 
GM-CSF. UMCs caused decreased endocytic activity as measured by uptake of fluorescent 
dextran by immature dendritic cells (Saeidi et al., 2013). 
 GVHD 
A recent study reported a clinical test for the immunosuppressive potential of UMCs in 
GVHD (Hu et al., 2013). The third party culture of expanded UMCs was transplanted into 
patients with severe, steroid-resistant acute GVHD (aGVDH). The aGVHD improved 
dramatically after each of four infusions of UMCs into the two patients. No adverse effects were 
noted (Wu et al., 2011). Nineteen patients with steroid-resistant severe aGVHD received in vitro 
expanded UMCs infusion treatment (Chen et al., 2012). Eleven patients had a complete response 
and survived. The other treated patients had partial and no response before they died because of 
aGVHD and infection. No patients had side-effects during or immediately after infusions and no 
UMC-related tumorigenesis was detected. 
 Lupus 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease (Batsali et al., 
2013). It has recently been reported that transplantation of UMCs in patients with severe and 
refractory SLE resulted in clinical and serologic improvement. Disease remission may be 
associated with an increase of T-regulatory cells in peripheral blood along with a decrease in 
serum IL-4 resulting in inhibiton of humoral activity (Sun et al., 2010). Another recent study 
demonstrated that allogeneic UMCs provided clinical benefit in diffuse alveolar hemorrhage, a 
rare complication of SLE with high clinical mortality (Shi et al., 2012). 
 Other therapeutic potentials of UMCs 
Properties of UMCs make them as the highly effective candidate for stem cell based 
therapies. UMCs can overcome three major hurdles of stem cell based clinical treatment. They 
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have high proliferative potential and are able to reach high cell numbers in a short time. They 
have low immunogenicity and do not produce tumors after transplantation (Bongso et al., 2008). 
Porcine umbilical cord matrix stem cells (PUCs) modify their morphology and 
neurochemical phenotype to resemble neural cells and survive 6 weeks in brain of rats after local 
xenotransplantation without immune suppression therapy (Weiss et al., 2006). Undifferentiated 
human UMCs were transplanted into the brain of hemi-parkinsonian immune-competent rats. 
There was a significant decrease in apomorphine-induced rotations at 4-12 weeks post 
transplantation in Parkinson’s disease (PD) rats compared to PD rats that received a sham 
transplantation (Weiss et al., 2006). Fu et al (2006) induced UMCs in vitro toward dopaminergic 
neurons and then transplanted them into hemi-parkinsonian rats (without immunosuppression). 
They detected the transplanted cells 5 month later. UMCs transplantation prevented the 
progression of behavioral deterioration seen in untreated control rats (Fu et al., 2006). Xiong et 
al. (2011) showed that intrastrial infusion of either human UMCs or VEGF-expressing human 
UMCs to rotenone-induced parkinsonian rats resulted in a reduction of apomorphine-induced 
rotations and a revival of tyrosine hydroxylase (TH) immunoreactivity in the lesioned striatum 
and substantia nigra. Transplanted human UMCs could differentiate into dopaminergic neuron-
like cells in the lesions and VEGF expression significantly enhanced the neuroprotective effects 
by promoting dopaminergic neuron-orientated differentiation of human UMCs (Xiong et al., 
2011).  
Oct-4 (+) rat UMCs was transplanted into the brains of rats experiencing the global 
cerebral ischemia caused by cardiac arrest and resuscitation. The transplanted rats had reduced 
neuronal loss due to a rescue phenomenon (Jomura et al., 2007) compared to controls. 
Intracerebral transplantation of xenogeneic UMCs accelerated neurologic function recovery in 
rat with intracerebral hemorrhage. The underlying mechanism may be due to their ability to 
inhibit inflammation and promote angiogenesis (Liao et al., 2009a). Donor UMCs transplanted 
into a rat model of stroke rarely adopted a neural cell identity after brain transplantation. 
However UMCs treatment substantially increased vascular density and vascular endothelial 
growth factor and basic fibroblast growth factor expression in the hemisphere of the stroke. 
UMC transplantation accelerated neurologic functional recovery of the rats after stroke and this 
may be due to their promoting angiogenesis (Liao et al., 2009b).  
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Intramyocardial transplantation of UMCs has been shown to improve cardiac function in 
a rat myocardial infarction model (Wu et al., 2007b,c). Locally transplanted UMCs differentiated 
into cardiomyogenic cells in ischemic myocardium and they incorporated into the 
neovascularized foci. UMCs contributed to neovascularization as a result of a direct 
incorporation of the cells into the ischemic myocardium, although other mechanism couldn’t be 
ruled out. Potentially stimulation of proangiogenic factors, local stimulation of angiogenesis, or 
chemoattraction of endogenous stem/progenitor cells could be involved. In vivo experiments 
showed a marked improvement of left ventricular ejection fraction (LVEF) assessed by 
echocardiography (ECG) (Wu et al., 2009a).  
Local administration of UMCs in the eyes of a rodent model of retinal disease exhibited 
histological evidence of photoreceptor rescue. Transplanted UMCs may enhance survival of 
photoreceptor cells by secreting growth factors. UMCs have been reported to increase production 
of brain derived neurotrophic factor (BDNF) as well as FGF2 compared to placenta-derived 
MSCs (Lund et al., 2007).  
Human UMCs transplanted into the ischemic cortex of rats, after treating with neuronal 
conditioned medium or control medium, caused a trend toward less infarct volume and 
significantly less atrophy compared with the control group. Rats receiving UMCs showed 
improvement in motor function, greater metabolic activity of cortical neurons and better 
revascularization in the infarct (Lin et al., 2011).  
UMCs have been applied as cellular therapy to combat cancer. Rachakatla et al. (2008) 
engineered human UMCs to secrete interferon-β. The cells migrated and engrafted near or within 
lung tumors and not in other tissues after intravenous transplantation. The administration of 
genetically modified UMCs combined with a low dose of 5-fluorouracil in immunodeficient 
mice resulted in more reduction of the tumor burden and metastasis than compared to either 
treatment alone (Rachakatla et al., 2008).  
A more recent study has reported the ability of UMCs transplanted systemically to reduce 
the growth of human breast carcinoma cells in vivo in a mouse xenograft model. The human 
UMCs attenuated DNA synthesis, increased G2 populations, and inhibited colony growth of co-
cultured breast carcinoma cells. Reduced growth of cancer cells is mainly by attenuation of Erk-
1/2 and PI3 K/Akt signaling and potentially an activation of intrinsic apoptosis (Ayuzawa et al., 
2009). Antitumor properties of UMCs do not seem to be specific only to breast cancer cells, but 
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was also demonstrated for osteosarcoma and ovarian carcinoma cell lines in vitro. UMC 
conditioned medium and cell lysate inhibit the growth of those cancer cell lines by inducing 
cancer cells to undergo metaphase arrest, apoptosis and autophagy (Gauthaman et al., 2013). Co-
culture of rat UMCs with pancreatic carcinoma cells caused G0/G1 arrest and significantly 
attenuated the proliferation of carcinoma cells. In vivo mouse studies showed engrafted rat 
UMCs decreased the peritoneal tumor burden after intraperitoneal transplantation and increased 
mouse survival (Doi et al., 2010). Naïve rat UMCs attenuated mammary tumor growth at least in 
part by enhancing host anti-tumor immune responses. They significantly increased lymphocyte 
infiltration in the tumor tissues and that the penetrated lymphocytes, primarily CD8+ T-cells and 
NK cells, and induced tumor cell death causing regression of tumors. The UMCs caused 
lymphocyte infiltration in the tumor tissues by increasing monocyte chemotactic protein-1 
(MCP-1) secretion from rat UMCs (Kawabata et al., 2013).  
Human UMCs transplanted in CCl4-induced acute hepatic failure engrafted and 
differentiated to functional hepatocytes. However, rescue from acute liver failure (ALF) seems to 
be through paracrine effects to stimulate endogenous liver regeneration rather than hepatic 
differentiation. Engrafted UMCs were more effective in down-regulating the expression of 
systemic inflammatory cytokines such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-
6 and IL-10 compared to transplanted adult hepatocytes. Direct transplantation of native human 
UCMs can rescue ALF and repopulate livers of NOD-SCID mice through paracrine effects to 
stimulate endogenous liver regeneration rather than hepatic differentiation for compensated liver 
function, which is the primary effect of adult hepatocytes (Zhang et al., 2012b).  
UMCs exhibit a promising potential to ameliorate endometrium damage. Human 
endometrial stromal cells that were damaged by exposure to mifepristone showed increased 
proliferation and decreased apoptosis when they were co-cultured in vitro with UMCs (Yang et 
al., 2011). 
 Migration of MSCs 
The migration or homing ability of MSCs to inflamed and ischemic tissues is thought to 
be due to the expression of chemokines or surface receptors. BM-MSCs were shown to express 
C-X-C chemokine receptor type 4 (CXCR4), the receptor for the chemokine stromal-derived 
factor-1 (SDF-1) and C-X-C chemokine receptor type 3 (CXCR3), the receptor for fractaline. 
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SDF-1 is predominantly localized in ischemic regions. BM-MSC migration and localization is 
mediated by the CXCR4/SDF-1 reaction (Wang et al., 2008b; Yu et al., 2010). Also, carcinoma 
fibroblasts derived from breast cancer secrete SDF-1 in vitro and MSC homing is mediated by 
SDF-1/CXCR4 signaling (Huang et al., 2010). A cocktail of the cytokines SCF, IL-6 and HGF 
up-regulate expression of CXCR-4 and this induction might be a potential strategy to improve 
engraftment of MSC (Shi et al., 2007). Expression of CXCR4 has been reported in human UMCs 
(Weiss et al., 2006) and it most likely plays an important role in homing of the cells to infarcted 
myocardium following acute myocardial infarction (Ghadge et al., 2011). 
The passage number of MSCs used is important for homing ability as MSCs have been 
shown to gain or lose certain surface receptors during culture and this might influence their 
migration capability. Freshly isolated MSCs have enhanced homing ability compared to their 
culture-expanded counterparts (Rombouts and Ploemacher, 2003). CXCR4 is usually expressed 
in lower levels on the surface of culture-expanded MSCs (Wynn et al., 2004). However, treating 
MSCs with a cocktail of cytokines in culture has been shown to induce higher surface expression 
of CXCR4 and enhanced homing ability (Shi et al., 2007). Simulating ischemic environments in 
culture is representative of MSCs niche and may increase MSCs motility. Hypoxic 
preconditioning increased MSCs migration through Matrigel and on tissue culture plastic by up-
regulating of matrix metalloprotease (MMPs) compared to MSCs maintained in normoxic 
environment (Annabi et al., 2003;  Rosova et al., 2008)   
For MSC migration experiments, the timing of delivery, number of cells delivered and 
site of infusion may affect the engraftment efficiency and the destination of exogenously 
delivered cells. MSCs were found to engraft in the myocardium at higher rates 1 day after 
myocardial infarction (MI) as compared to 14 days after MI, indicating that MSCs engraft in 
response to acute MI (Schenk et al., 2007). Omori et al (2008) reported that transplanting higher 
numbers of MSCs and MSCs delivered sooner after starting of ischemia resulted in higher 
engraftment rates (Omori et al., 2008). In a rat model of brain injury, Wu et al (2008) 
demonstrated systemic infusion of 1x10
6
 BM-MSCs improved neurological function however no 
additional enhancement was observed when 3x10
6
 MSCs were infused (Wu et al., 2008).  
The confluency of cultured MSCs prior to therapeutic infusion also affects migration 
potential. Lee et al. (2009) investigated the differences between low-passage and low-density 
cultures of MSCs. Six surface markers were found preferentially expressed on early passage 
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MSCs in low confluency cultures: podocalyxin-like protein PODXL, CD49f, CD49d, cMet, 
CXCR4, and CX3C chemokine receptor 1 (CX3CR1) (Lee et al., 2009). De Becker et al. (2007) 
demonstrated that high culture confluence inhibited transendothelial migration in MSCs by 
increasing the production of a natural matrix MMP inhibitor, TIMP-3. Exposure of MSCs to 
hypoxic conditions increased CXCR4 and CX3CR1 expression, which leads to increased 
migration in response to SDF-1α (Hung et al., 2007).  
The site of MSCs delivery may impact the route that MSCs travel to reach the target 
organ. Systemic administration can be achieved by intravenous (IV) injection, intraperitoneal 
(IP) injection, intra-arterial (IA) injection or intracardiac (IC) injection. IC and IA delivery 
resulted in higher engraftment rates than IV delivery in models of MI (Barbash et al., 2003; 
Freyman et al., 2006). Also, IA injection close to the site of brain injury significantly enhanced 
homing to the brain compared to IV injection (femoral vein) (Walczak et al., 2008). The 
advantage of IA injection may be involved in reducing of aggregation of MSCs within filtering 
organs such as the lung, liver or spleen often observed in IV delivery (Barbash et al., 2003; 
Kraitchman et al., 2005; Sackstein et al., 2008). However, IA may increase the possibility of 
microvascular occlusions (Walczak et al., 2008). IP injection has rarely been used for MSCs 
transplantation but IP administration has been employed to deliver MSCs to murine fetuses in a 
mouse model of muscular dystrophy (Chan et al., 2007). The distribution and migratory 
properties of systemically injected MSCs is helpful in studying homing efficiency. MSCs, after 
intravenous delivery, are found at low or very low frequencies in most target organs shown by 
various tracking techniques as fluorescent protein labeling (Devine et al., 2003; Kawada et al., 
2004; Nagaya et al., 2004), transduction with reporter genes (Horita et al., 2006), detection of 
human genes in animal recipients (Barbash et al., 2003; Mahmood et al., 2005; Francois et al., 
2006), sex-linked chromosome gene for sex mismatch transplants (Ortiz et al., 2003; Jiang et al., 
2006), histology (Morigi et al., 2008), immunohistochemistry (Mahmood et al., 2005; Horita et 
al., 2006, Fatar et al., 2008; Omori et al., 2008), real-time PCR (Devine et al., 2003; Ortiz et al., 
2003) and fluorescent in situ hybridization (Ortiz et al., 2003; Jiang et al., 2006). Devine et al 
(2003) demonstrated a high number of transplanted cells observed in gastrointestinal tissues and 
a relatively high number of cells also observed in the kidney, lung, liver, thymus, and skin. The 
levels of engraftment in these tissues were estimated, ranging from 0.1% to 2.7% of the 
administered cells.  
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In non-injury models, by detecting enhanced green fluorescent protein (GFP)-transfected 
murine MSC, the highest frequency of GFP-positive organs were found in the lungs, liver, 
kidney, skin, and gut among investigated tissues 24 h after MSC intravenous transplantation 
(Deak et al., 2010).  Non- or minimally-invasive procedures to track MSC migration in real time 
was performed using various techniques including magnetic resonance imaging (MRI) on 
superparamagnetic iron oxide (SPIO) nanoparticle-labeled MSCs (Hsiao et al., 2007; Song and 
Ku, 2007; Reagan and  Kaplan, 2011), combined single-photon emission CT (SPECT)/CT 
scanning (Kraitchman et al., 2005) and quantum dot tracking (Yukawa et al., 2012). These 
techniques have enhanced the ability to investigate MSC homing as well as the behavior and 
organ-specific accumulation of transplanted MSCs. MRI cell tracking using SPIO is thought to 
be the lowest risk alternative for monitoring stem cell activity in humans due to the widely 
available data regarding the risk of MRI and the fact that SPIOs are Food and Drug 
Administration approved.  
Using SPECT/CT imaging in an acute myocardial infarction model, the initial 
localization of BMMSCs was observed in the lung and the cells moved to nontarget organs such 
as the liver, kidney, and spleen within 24 to 48 h after infusion. An increase in MSCs was found 
in the infarcted heart tissue with a simultaneous decrease in the initial concentration of MSCs in 
the lung 24 h after infusion, and MSCs persisted until 7 days after injection (Kraitchman et al., 
2005).  
The labeling of BMMSCs with bioconjugated quantum dots (QDs) does not alter the self-
replication and differentiation potential of MSCs into chondrogenic, osteogenic, and adipogenic 
cells (Shah et al., 2007). MSCs labeled with QDs are very useful not only for tracking MSCs but 
also in investigating the behavioral changes of cells when MSCs are injected in combination with 
chemical compounds such as drugs like heparin. Mice induced to acute liver failure and then 
transplanted intravenously with ADCs without heparin treatment showed accumulation of almost 
all injected ADCs in the lungs within 10 minutes. However, when heparin was used in 
combination with ADCs, the accumulation of the transplanted stem cells was found not only in 
the lungs but also in the liver, and the accumulation increased by about 30% in the injured liver 
(Yugawa et al., 2012). Collectively, studies using different methods for tracking MSCs have 
shown most of MSCs located in the lung after transfusion and then they moved gradually to 
injured sites or to the liver, spleen, kidney, and bone marrow.  
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Intraperitoneal administration of BM-MSCs and osteogenic-induced BM-MSCs has been 
studied in rats. Distribution of BM-MSCs injected peritoneally was tracked by detecting Y-
chromosome specific sequences by amplifying with PCR. Regardless of cell culturing protocols 
prior to transplantation, they were found to migrate and engraft into lung, bone marrow, thymus, 
liver and spleen of recipients after 1 week of intraperitoneal injection (Wilson et al., 2010). 
It is unclear if MSCs actively home to tissues using leukocyte-like cell-adhesion and 
transmigration mechanisms (Springer, 1994) or become passively entrapped in small diameter 
blood vessels. It is possible that MSCs become passively arrested in capillaries or microvessels 
including arterioles and postcapillary venules. Active arrest of MSCs within inflamed tissues is 
supported by studies of integrin blocking and P-selectin knockouts. Blocking of MSCs β1-
integrin, the adhesion molecule that governs the arrest of leukocytes on activated endothelium, 
reduces the engraftment in ischemic myocardium (Ip et al., 2007). Using P-selectin knockout 
mice, Ruster et al. (2006) reported that fewer MSCs slowed down in postcapillary venules 
compared to wild type mice. These results suggest that the engraftment of MSCs within target 
tissues depends on specific molecular interactions for extravasation prior to the migration step. It 
has been reported that MSCs transmigrate through non-activated endothelial monolayers via 
VCAM/VLA-4 and β1-integrin interaction including MMP-2 secretion and that they tend to 
integrate within the endothelial layer instead of completing diapedesis as observed for leukocytes 
(Steingen et al., 2008). The time course for transmigration was 240 min, which is longer than 
leukocytes which take 5-20 minutes (Ley et al., 2007).  
It is generally assumed that factors released upon tissue damage or apoptosis mobilize 
and recruit stem and progenitor cells to the damaged site, where they proliferate and differentiate 
and eventually replace the damaged tissues (Gurtner et al., 2008). Chemokines released from 
tissues or endothelial cells likely promote activation of adhesion ligands, transendothelial 
migration, chemotaxis and subsequent retention in surrounding tissue. Numerous studies have 
confirmed that systemically infused MSCs can migrate to injured, inflamed tissues and exert 
therapeutic effects (Chapel et al., 2003; Chavakis et al., 2008).  
BM-MSCs, delivered intravenously to rats following myocardial infarction localize in the 
infarct region and improve ventricular function, while MSCs delivered intravenously to 
noninfarcted rats localized to the bone marrow (Saito et al., 2002). In addition, localized 
abdomen irradiation has been shown to significantly enhance MSC homing specifically to 
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radiation-injured tissues in mice (Mouiseddine et al., 2007). Human ADCs infused into the tail 
vein mobilized to cell-damaged areas in an allergic rhinitis animal model (Cho et al., 2009). 
 Monocyte chemotactic protein-1 (MCP-1) is typically expressed at site of inflammation 
and is known to up-regulate adhesion molecules on the endothelial surface and increase 
endothelial permeability (Stamatovic et al., 2003). Using transgenic mice genetically modified to 
express MCP-1 in the myocardium, Belema-Bedada et al (2008) reported that MSCs expressed 
surface C-C chemokine receptor type 2 (CCR2), a specific receptor of MCP-1, and migrated and 
then were engrafted with high frequency to myocardium of transgenic mice compared to normal 
mice.  
The direct interaction of CCR2 with MCP-1 is crucial (Belema-Bedada et al., 2008). 
MSCs secrete proteases that regulate transmigration and invasion of the basement membrane of 
endothelium and degrade extracellular matrix (ECM) during chemotaxis. De Becker et al (2007) 
demonstrated that blocking antibodies toward MMP2 and SiRNA knockdown of MMP2 reduced 
trans-endothelial migration in vitro (De Becker et al., 2007). Induction of expression of specific 
MMPs and their inhibitors MMP-2, membrane type 1 MMP (MT1-MMP), tissue inhibitor of 
metalloproteinase 1 (TIMP-1), and tissue inhibitor of metalloproteinase 2 (TIMP-2) in human 
MSCs by inflammatory cytokines promotes directed cell migration across reconstituted basement 
membranes in vitro. Detailed studies by RNA interference revealed that gene knock-down of 
MMP-2, MT1-MMP, or TIMP-2 substantially impaired MSCs invasion, whereas silencing of 
TIMP-1 enhanced cell migration, indicating opposing roles of these TIMPs in this process (Ries 
et al., 2007). The interactions of SDF-1α and CXCR4 were found to mediate the trafficking of 
transplanted BM-MSCs in a rat model of left hypoglossal nerve injury.  
Inflammatory cytokines TGF-β1, IL-1β, and TNF-α up-regulate the production of MMPs 
in MSCs, resulting in a strong stimulation of chemotactic migration through the extracellular 
matrix, while the chemokine SDF-1α exhibited minor effects on MMP/tissue inhibitor of 
metalloproteinase (TIMP) expression and cell invasion (Ries et al., 2007). BM-MSCs are 
mobilized by chemokines that are present in the supernatants of primary cultures of human 
pancreatic islets cultured in vitro and in vivo. CXCR-4/CXCL-12 and CX3CR1/CX3CL-1 axes 
played the major role for homing of BM-MSCs to the inflamed region (Sordi et al., 2005). 
Human ADCs migrate in response to a variety of growth factors and cytokines including platelet-
derived growth factor (PDGF), TGF-β1, TNF-α, and SDF-1α. Pre-treatment of ADCs with TNF-
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α caused enhanced migratory activity compared to the non-pretreated control group (Baek et al., 
2011). These results indicate that enhancement of the homing capacity of MSCs can be achieved 
by modulating the response of MSCs to a variety of growth factors and cytokines, thereby 
improving their therapeutic potential.  
A key player in MSC migration is the CXCR4-SDF-1α axis. Many studies have focused 
on ways to enhance the functional expression of CXCR4 in MSCs to migrate toward chemotactic 
SDF-1α secreted at injury sites. Modification of CXCR4 expression with retroviral 
overexpression (Cheng et al., 2008b), mRNA transfection of CXCR4-GFP (Ryser et al., 2008) 
and cytokine pretreatment especially TNF-α have resulted in increased migration toward SDF-
1α in vitro (Xiao et al., 2012). Maijenburg et al. (2012) investigated gene expression profiles 
involved in the process of MSC migration and found 12 differentially expressed genes in 
migratory MSCs compared to nonmigrating MSCs. Among them, the nuclear receptors Nur77 
and Nurr1 showed the highest expression in migratory MSCs. The expression of these receptors 
rapidly increased under stimulation with SDF-1α and PDGF-BB. Genetically engineered MSCs 
overexpressing Nur77 or Nurr1 showed enhanced migration toward SDF-1α and decreased the 
proportion of cells in the S-phase of the cell cycle (Maijenburg et al., 2012).  
The up-regulation of the α4 subunit of the VLA-4-integrin on MSCs using an adenovirus 
vector resulted in successful dimerization with β1-integrin and increased the homing ability of 
MSCs to the bone marrow by more than 10 fold as compared to non-transduced MSCs (Kumar 
and Ponnazhagan, 2007). Human MSCs do not express the surface adhesion molecules P-selectin 
glycoprotein ligand-1 (PSGL-1) and sialofucosylated glycoform of the CD44 protein (HCELL) 
specific to E-selectin expressed on bone marrow vasculature cells. Sackstein et al. (2008) 
enzymatically modified the native CD44 glycoform on MSCs into hematopoietic cell ligands that 
bind specifically to E-selectin of bone marrow endothelial cells and observed increased MSC 
migration to the bone marrow (Sackstein et al., 2008).  
In a variety of clinical indications, MSCs are administered to damaged tissues at the 
subchronic or chronic phases of injury at which time the migratory signals for MSCs may be 
minimal or absent. Electrical current applied to wounded tissue activates and stimulates 
migration of fibroblasts which play a critical role in wound healing (Choi et al., 2011). Zhao et 
al. (2011a) demonstrated that physiological electric field (EF) of ~25 mV/mm in vitro directed 
the migration of cultured BMMSCs mainly to the anode. Increasing the EFs enhanced the 
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migration of the MSC and the response peaked at 300 mV/mm at a rate of 42±1 μm/h. This is 
around double the migration rate of the control (no EF). Of importance, EF did not influence cell 
senescence, phenotype, or the osteogenic potential of MSCs, regardless of passage number 
within the range tested (P3–P10) (Zhao et al., 2011). Moreover, electrical stimulation (ES) could 
ameliorate survival of MSCs after local transplantation. Wu et al. (2011) demonstrated that 
implanted spike wave electrical stimulation (ES) improved the survival of BMMSCs after 
transplantation compared to BM-MSCs transplantation or ES treatment alone using an in vivo rat 
model of spinal cord injury. Furthermore, analysis of functional parameters demonstrated 
improved functional recovery in the BM-MSCs + ES groups (Wu et al., 2011). 
 Therapeutic and clinical application of MSCs 
Mesenchymal stem cells (MSCs) have generated a great amount of interest over the past 
decade as novel therapeutics for a variety of diseases. Currently, MSC based clinical trials have 
been conducted for numerous kinds of pathological conditions, with some completed trials 
demonstrating MSCs safety and efficacy. In vitro and in vivo animal and human clinical data 
indicate broad fields of application for MSCs. Overwhelming evidence of usefulness of MSCs in 
regenerative medicine, tissue engineering and immune therapy have been reported. The first 
clinical trial using culture-expanded BM-MSCs was carried out in 1995 and the patients were 
recipients of autologous cells (Lazarus et al., 1995). Since, a number of clinical trials have been 
conducted to test the feasibility and capability of MSCs-based therapy. Most of the trials are in a 
mixture of PhaseI/II studies. A number of these trials are in Phase III. Immune rejection, 
autoimmunity and bone/cartilage related diseases are the most frequent clinical trials using 
MSCs (Trounson et al., 2011). 
 GVHD 
Acute GVHD occurs after allogeneic hematopoietic stem cell transplantation and is 
associated with high morbidity and mortality (Messina et al., 2008). Corticosteroids are used for 
initial treatment of acute GVHD. However, they are only effective for some patients. The 
immunomodulatory properties of MSCs have stimulated interest in their application for GVHD. 
The first report of successful use of MSCs for treatment of severe steroid-refractory acute GVHD 
was in 2004 (Le Blanc et al., 2004). Ex vivo expanded haplo-identical human BM-MSCs were 
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used. Intravenously infused MSCs had a striking immunosuppressive effect and the cells seemed 
to have had a rapid healing effect on the damaged gut epithelium.  
In phase I and phase II clinical trials, with the median dose as 1.4x10
6
 cells per kg 
bodyweight, 55 steroid resistant severe acute GVHD patients were treated with single or multiple 
infusions of BM-MSCs derived from HLA-identical sibling donors, haploidentical donors, and 
third-party HLA-mismatched donors. The results showed complete response in 30 patients, 
partial response in 9 patients, no response in 3 patients and progressive disease in 13 patients. 
(Le Blanc et al., 2008). Of 31 acute GVHD patients treated in another phase II clinical trial using 
allogeneic MSCs (Prochymal®), 94% showed initial response to MSCs, 77% showed complete 
response (CR), and 17% showed a partial response (PR) with no infusion related toxicity or 
ectopic tissue formation. A CR was defined as the absence of symptoms referable to acute 
GVHD in all organs. A PR was defined as a decrease by at least 1 GVHD stage in any 1 organ 
system without deterioration in others (Kebriaei et al., 2009). 
 Crohn’s disease 
Therapeutic benefits of MSCs have also been observed for Crohn’s disease, a type of 
inflammatory bowel disease. Patients with refractory Crohn’s disease were infused inravenously 
with autologous BM-MSCs and showed clinical response by significantly decreasing of Crohn's 
disease activity index (CDAI) (Duijvestein et al., 2010). In vitro co-culture of ADCs and 
peripheral blood mononuclear cells (PBMCs) induced by superantigen Staphylococal enterotoxin 
showed inhibitory effects measured by cytokine secretion and T-cell proliferation. The inhibitory 
effect was partially reversed when PBMCs and ADCs were separated by a semi-permeable 
transwell membrane. IP injection of ADCs significantly ameliorated the clinical and 
histopathological severity of colitis. It abrogated weight loss, diarrhea and inflammation and 
increased the survival rate. The therapeutic effect was associated with down-regulation of the 
Th1-driven inflammatory responses and APCs maturation. Reduced levels of inflammatory 
cytokines (TNF-α, IFN-ɣ, IL-6, IL-1β and IL-12) were observed. Also, increasing levels of the 
anti-inflammatory/regulatory cytokine, IL-10, as well as regulatory T cells (Treg) in affected 
organs was detected (Gonzalez-Rey et al., 2009; Panes and Salas, 2009).  
Ko et al. (2010) recently showed that MSCs coated with antibody against addressin, a 
mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), and intravenously injected 
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into dextran sulfate sodium (DSS)-induced colitis mice increased efficacy of treatment, as 
indicated by survival rate, body-weight recovery, colon length and histological score. It was 
suggested that improved therapeutic effects are induced by increased MSC delivery to sites of 
inflammation due to the addressin antibody coating. Liang et al. (2012) reported that seven 
inflammation bowel disease (IBD) received a single IV infusion of 1 × 106 allogenic MSC from a 
related healthy donor. All seven patients experienced improvement in symptoms and five of 
seven patients had complete remission. 
 Multiple sclerosis (MS) 
Experimental autoimmune encephalomyelitis (EAE) is an animal model of MS. MS is an 
autoimmune disease of the CNS and involves in T cells and macrophages. Currently, the 
established treatment for EAE is based on targeting T cells to induce immunosuppression or 
tolerance. Human and mouse MSC treatment of EAE demonstrates improved clinical progress, 
stimulation for tissue repair, decreased demyelination, and infiltration of the CNS by T cells and 
macrophages. Injected MSCs accumulate in the CNS, reduce the extent of damage and increase 
oligodendrocyte lineage cells in the lesion areas. Host immune responses were also influenced by 
transplanted MSCs. Inflammatory T-cells including interferon gamma producing Th1 cells and 
IL-17 producing Th17 inflammatory cells, and their associated cytokines, were reduced along 
with concomitant increases in IL-4 producing Th2 cells and anti-inflammatory cytokines (Bai et 
al., 2009). Intravenous administration of ADCs before disease onset significantly reduces the 
severity of EAE by immune modulation and decreases spinal cord inflammation and 
demyelination. 
Intravenous injection of MSCs was shown to suppress EAE through induction of 
peripheral immunomodulation as the transplanted cells were found in spleen and cervical lymph 
nodes (Gerdoni et al., 2007). In chronic established EAE, administration of ADCs significantly 
ameliorated the disease course, reduced both demyelination and axonal loss, and induced a Th2-
type cytokine shift in T cells. ADCs suppressed the autoimmune response in early phases of the 
disease as well as by inducing local neuroregeneration of endogenous progenitors in animals 
with established disease (Constantin et al., 2009).  
BM-MSCs, when intraperitoneally delivered accessed the CNS in minimal numbers. 
They were found in barely detectable levels of CNS infiltration, and produced a pronounced 
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therapeutic impact of these cells on EAE severity (Gordon et al., 2008). MSCs delivered IP 
infiltrate lymph nodes and this may be highly relevant to their mode of action. The engrafted 
MSCs induced peripheral T-cell tolerance to the immunising antigen myelin oligodendrocyte 
glycoprotein, thereby leading to a large improvement in clinical course, reduction of 
demyelination, and CNS infiltration by T cells and macrophages (Parekkadan et al., 2008). 
 Amylotrophic lateral sclerosis 
Amylotrophic lateral sclerosis (ALS) is a degenerative disease which occurs due to loss 
of upper and lower motor neurons in the cerebral cortex, brainstem, and spinal cord. ALS leads 
to death within five years after first appearance of symptoms. In a phase I/II study patients with 
MS and ALS were treated with intravenous MSC infusion which led to an increase in the 
proportion of CD4+ CD25+  Treg cells in the peripheral blood of the patients (Karussis et al., 
2008).  
Thus, at least two different mechanisms, namely peripheral modulation of pathogenic 
immune responses and neuroprotection, provide a strong rationale for the use of MSCs in 
therapeutic trials for neurological diseases characterized by inflammation and neural damage, 
such as MS (Uccelli et al., 2011). 
 Diabetes 
Diabetes mellitus (DM) is characterized by hyperglycemia resulting from defects in 
insulin secretion, insulin action, or both. Type I DM is characterized by beta-cell destruction, 
typically by an autoimmune T cell-mediated mechanism, which usually leads to an absolute 
deficiency of insulin. Type 2 diabetes or adult onset diabetes is defined by the inability of insulin 
to properly regulate glucose concentrations in the blood. DM is implicated in pathologies such as 
adult blindness, kidney failure, amputation of legs and feet, pregnancy complications, and heart 
attack (Mishra et al., 2010). 
In vitro differentiation of MSCs into insulin-producing cells (IPCs) is reported. The 
protocols include a combination of nicotinamide, activin A, and β-cellulin in high glucose 
medium (Karaoz et al., 2013). The differentiated cells show a similar morphology to that of 
pancreatic islet-like cells with high expression of Pdx1, insulin and glucagon genes and glucose 
dependent insulin production (Sun et al., 2007).  
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UMCs have been differentiated to IPCs. Real-time RT-PCR detected the expressions of 
insulin and other pancreatic beta-cell-related genes (Pdx1, Hlxb9, Nkx2.2, Nkx6.1, and Glut-2) 
in these islet-like cell clusters. The islet-like clusters possessed insulin-producing ability in vitro 
and in vivo and released insulin and C peptide in response to physiological glucose 
concentration. The hyperglycemia and glucose intolerance in streptozotocin-induced diabetic rats 
was significantly alleviated after xenotransplantation of islet-like cell clusters, without the use of 
immunosuppressants (Chao et al., 2008).  
Combined transfection of the three transcriptional factors, PDX-1, NeuroD1, and MafA, 
causes differentiation of bone marrow MSCs into insulin-producing cells (Guo et al., 2012). 
Undifferentiated human ADCs were able to adopt a pancreatic endocrine phenotype ex vivo and 
they expressed the pancreatic endocrine transcription factor, Isl-1. Incubation of ADCs in 
differentiation medium that contained nicotinamide, activin-A, exendin-4, hepatocyte growth 
factor, and pentagastrin resulted up-regulation of pancreatic developmental transcription factors 
Isl-1, Ipf-1, and Ngn3. This protocol showed the possibility to generate IPCs from adipose 
derived MSCs (Timper et al., 2006).  
The immunomodulatory capability of MSCs is considered equally important for diabetes 
treatment especially in diabetes type I. A preclinical study suggested that anti-diabetic effect of 
mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability 
to modulate immune response and to modify the pancreatic microenvironment. Syngeneic MSCs 
intravenously administered were found engrafted in secondary lymphoid organs and this 
correlated with a systemic and local reduction of auto-aggressive T cells together with an 
increase in regulatory T cells. In addition, the cytokine profile was shifted from proinflammatory 
to antinflammatory. MSC transplantation did not reduce pancreatic cell apoptosis but recovered 
local expression and increased the circulating levels of epidermal growth factor, a pancreatic 
trophic factor (Ezquer et al., 2012). However, Ho et al. (2012) suggested that the lasting 
therapeutic effects of MSCs were due to MSC engraftment and differentiation into insulin 
producing cells and also due to immunomodulation properties (Ho et al., 2012).  
BM-MSCs infused intravenously contributed to amelioration of insulin resistance by 
peripheral insulin target tissues and increased the expression of glucose transport protein 
(GLUT4), phosphorylated insulin receptor substrate 1 (IRS-1) and protein kinase B (Akt). 
Transplanted MSCs alleviated hyperglycemia in rats with type 2 diabetes (T2D). Infusion of 
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MSCs during the early phase not only promoted beta-cell function but also improved insulin 
resistance whereas infusion in the late phase only affected the insulin resistance (Si et al., 2012).  
Usage of MSCs was also implemented in several diabetes related complications like 
cardiomyopathy, nephropathy, polyneuropathy and diabetic wounds. Chronic hyperglycemia is 
responsible for diabetic cardiomyopathy (DCM) which is characterized by hypertrophy and 
apoptosis of cardiomyocytes as well as increased collagen deposition. 
Intravenous administration of BM-MSCs improved myogenesis and angiogenesis and 
reduced myocardial fibrosis. In a glycerol-induced acute renal failure (ARF) of mice model, 
intravenous administration of BM-MSCs showed improvement of kidney function and 
regeneration of glomerular structure. Engrafted MSCs were able to differentiate into tubular 
epithelial cells and enhanced tubular proliferation resulting in reconstitute necrotic segment of 
diabetic kidneys (Herrera et al., 2004).  
Diabetic polyneuropathy (DPN) involved in microvascular injury is the most common 
complication of DM which is characterized by damage to nerve fibers. Although studies 
suggested that MSCs have the capacity to differentiate into neural cells in vitro, this was not 
observed during in vivo studies using diabetic rat model. BM-MSCs transplanted into hind limb 
skeletal muscles of streptozotocin (STZ)-induced diabetes rats were able to engraft and secrete 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The 
paracrine action of MSCs ameliorated DPN (Shibata et al., 2008).  
Studies on rats and mice showed that systematic and local administration of bone 
marrow-derived MSCs improves healing of diabetic wounds. MSC injection resulted in increase 
in several growth factors important for successful wound healing. Treatment with BMSC 
systemically or locally at the wound site improved the wound-breaking strength (WBS) of fascial 
wounds. The improvement in WBS was associated with an immediate and significant increase in 
collagen levels (type I–V) in the wound bed. In addition, treatment with BMSCs increased the 
expression of growth factors critical to proper repair and regeneration of moderately to markedly 
damaged tissue TGF-β, KGF, EGF, VEGF, PDGF (Kwon et al., 2008). 
 UMCs for treating diabetes 
In a phase I clinical trial, allogeneic Wharton’s jelly derived MSCs show long-term 
beneficial effects on newly diagnosed diabetes mellitus (DM) type 1 (T1DM) patients after 
intravenous transplantation (Hu et al., 2013a). Both the glycosylated hemoglobin (HbA1c) and C 
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peptide in transplanted patients were improved compared to either pre-therapy values or control 
patients during the follow-up period. These data indicate that transplantation of UMCs for the 
treatment of onset T1DM is safe and effective. However, the precise mechanisms are unknown 
(Hu et al., 2013a). 
 Heart 
The heart has limited capacity for self-renewal and undergoes remodeling with resulting 
depressed left ventricular function after acute myocardial infarction (MI). Investigations of 
MSCs as therapeutics for cardiac repair have resulted clinical trials (Williams and Hare, 2011). 
Autologous MSCs injected directly to infarcted regions showed engraftment into scarred 
myocardium and expressed the cardiomyocyte markers like α-actin, desmin, tropomyosin, and 
myosin heavy chain (Shake et al., 2002). In a swine model of chronic ischemic cardiomyopathy, 
allogeneic MSCs were transplanted by catheter-based trans-endocardial injections to engraft at 
the infarct and border zone. The MSCs differentiated into cardiomyocytes as indicated by 
expression of GATA-4, Nkx2.5, and α-sarcomeric actin. In addition, MSCs exhibited vascular 
smooth muscle and endothelial cell differentiation, contributing to large and small vessel 
formation. Infarct size was reduced with increasing regional contractility, myocardial blood flow 
(MBF) and left ventricular ejection fraction (LVEF) (Quevedo et al., 2009). In a double-blind, 
placebo-controlled, dose-range phase I trial, intravenous injection of MSCs in acute MI 
demonstrated a reduction in ventricular arrhythmias and improved pulmonary function whereas 
the patients had a 6% increase in LVEF at 3 months (Hare et al., 2009).  
Despite numerous studies on the transplantation of MSCs in patient and animal models, 
the mechanisms issues underlying the effect of MSC transplantation remains vague. A recent 
study suggested the importance of IL-6 secreted from MSCs in paracrine action that activated 
Janus kinase/signal transducers and activators of transcription (JAK/STAT3). The trophic 
cascade initiated by JAK/STAT3 signaling increased growth factor levels in multiple tissues, 
leading to elevated circulating HGF and VEGF. Synergistic actions of these trophic factors 
further activated the myocardial repair mechanisms orchestrated by the Ark, ERK and 
JAK/STAT3 (Shabbir et al., 2010). A recent study demonstrated that paracrine signaling resulted 
in increased survival of ventricular myocytes by Akt induced change in calcium signaling which 
resulted in antiapoptotic effect by transplanted MSCs (DeSantiago et al., 2012). 
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 Liver 
Liver transplant is the preferred solution in case of liver diseases but donor organ 
shortage is the main reason why whole organ or hepatocyte transplants frequently cannot be 
done. Therefore, generation of hepatocyte-like cells from MSCs has become a real alternative to 
the isolation of primary hepatocytes. Stock et al. (2010) reported MSCs isolated from human 
bone marrow could differentiate to human hepatocyte-like cells in vitro after culturing in 
medium containing 5-azacytidine, insulin, dexamethasone, insulin-transferrin-sodium selenite 
(ITS), epidermal growth factor (EGF) and hepatic growth factor (HGF). Differentiated MSCs 
adopted functional features of hepatocytes with expression of proteins of the cytochrome P450 
enzyme family, synthesis of glycogen and expression of hepatocyte markers on the protein level. 
Xenogenic transplantation of human hepatocyte-like cells into livers of immunocompromised 
mice undergoing hepatectomy was successful (Stock et al., 2010). In allylalcohol- (AA-) treated 
rat liver, xenografting of allogeneic MSCs by intrahepatic injection differentiated into 
hepatocytes-like cells which showed positive immunostaining for albumin, CK-19, CK-18, and 
asialoglycoprotein receptor (AGPR). Cell fusion between engrafted MSCs and recipient 
hepatocytes was not likely involved since both human and rat chromosomes were independently 
identified by fluorescence in situ hybridization (FISH). The differentiation appeared to follow 
the process of hepatic ontogeny, reprogramming of gene expression in the genome of MSCs, as 
evidenced by expression of the AFP gene at an early stage and the albumin gene at a later stage 
(Sato et al., 2005).  
Liver cirrhosis was induced in rats using thioacetamide (TAA) followed by 
transplantation with BM-MSCs into spleen and liver. There was engraftment and hepatic 
differentiation in the liver parenchyma. BM-MSCs-derived hepatocyte-like cells with oval 
morphology expressed CK19 (cytokeratin 19) and thy1 including finally producing albumin. 
MSC injection resulted in apoptosis of hepatic stellate or perisinusoidal cells and resultant 
resolution of fibrosis, but did not cause apoptosis of hepatocytes (Hwang et al., 2012). In a swine 
model of acute liver failure, placenta-derived MSCs transplanted via the portal vein not only 
supported liver regeneration but also prolonged host survival (66.7 vs. 0%) (Cao et al., 2012).  
 In rat liver fibrosis model, transplantation of BM-MSCs through intravenous injection 
has been shown to give the best results and protect the liver against fibrosis through IL-10 
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expression compared to intrahepatic, and intraperitoneal transplantation. Action of IL-10 is by 
inhibiting IL6, TNF-α and TGF-β cytokines that stimulate tissue fibrosis (Zhao et al., 2012).  
Non-induced and hepatocyte-induced MSCs have been used for the treatment of liver 
fibrosis. The MSC-derived hepatocyte-like cells engrafted in liver secrete growth factors that 
promote liver regeneration, suppress hepatic stellate cell activity, and secrete MMP, thereby 
removing deposited ECM (Takeda et al., 2005; Yannaki et al., 2005). Some studies have 
demonstrated that undifferentiated MSCs injected into rats with cirrhotic livers differentiated 
mainly into myofibroblasts and hepatic stellate cells and that both of these are promoters of liver 
fibrosis (Russo et al., 2006; Carvalho et al., 2008). However, phase I and II clinical trials for 
liver cirrhosis suggest that both differentiated (Kuo et al., 2008) and undifferentiated MSCs 
transplantation improved liver function (Kharaziha et al., 2009; El-Ansary et al., 2012a).  
Patients intravenously transplanted with 10
6
 MSCs/Kg of autologous BM-MSCs were 
followed up at 3 and 6 months after infusion. They showed partial improvement of liver function 
tests with elevation of prothrombin concentration and serum albumin levels, decline of elevated 
bilirubin and Model for End-Stage Liver Disease score (MELD) (El-Ansary et al., 2012a). 
Decompensated liver cirrhosis is a life-threatening complication of chronic liver disease. Thirty 
patients having a history of chronic HBV infection were intravenous transplanted with 5 x 10
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allogenic UMCs /Kg. This transplantation showed a significant reduction in the volume of 
ascites. UMCs therapy significantly improved liver function, as indicated by the increase of 
serum albumin levels, decrease in total serum bilirubin levels, and decrease in the MELD scores 
during one-year follow-up studies (Zhang et al., 2012c). 
 UMCs for liver therapies 
UMCs transplanted into the portal vein migrated and engrafted in fibrotic areas of 
chemically induced- liver fibrosis. Recovery of liver functions was observed with improved 
serum prothrombin time and serum albumin level. Immunohistochemical analysis showed 
engrafted UMCs produced albumin, HGF and MMPs. The transplanted UMCs may help to 
decrease liver collagen and may be useful for treating liver fibrosis (Lin et al., 2010). Liver 
injury induced by CCl4 administration was treated with human UMCs. Transplantation of UMCs 
suppressed serum transaminase activities and hepatocytes damage. Engrafted UMCs reduced 
hepatocyte apoptosis and promoted hepatocytes proliferation following the TUNNEL and PCNA 
stains (Yan et al., 2009). An investigation by Tsai et al. (2009) into the effect of human UMCs 
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on CCl4-induced liver fibrosis in rats have found that direct transplantation of UMCs into the 
liver reduced liver fibrosis significantly, as evidenced by Sirius red staining and a collagen 
content assay. The engrafted UMCs scattered mostly in the hepatic connective tissues and did 
not differentiate to hepatocytes. These undifferentiated HUMSCs appear to secrete a variety of 
bioactive cytokines that may restore liver function and promote regeneration (Tsai et al., 2009). 
 Kidney 
There are multiple reports of MSCs repopulating the damaged kidney. Ischemia-
reperfusion (IR) results in an inflammation response and fibrosis with immunosuppressive 
therapy are major causes of progressive renal failure after kidney transplantation. Intrarenal 
injection of bone-marrow-derived MSCs reduces kidney fibrosis after ischemia-reperfusion in 
cyclosporine-immunosuppressed rats. These effects were associated with a decrease in interstitial 
α-SMA accumulation and MMP2 activity, markers of fibrosis and renal remodeling (Alfarano et 
al., 2012). Initial studies reported that the exogenous administration of BM-MSCs via 
intravenous route to mice with acute renal injury could promote both structural and functional 
renal repair via the transdifferentiation of MSCs into tubular epithelium. Detection of MSCs at 
day 4 and day 29 after transplantation in the context of well-differentiated tubular epithelial 
lining indicated that MSCs repopulated the tubules, most likely by recruitment at peritubular 
sites where the Y-chromosome MSCs were also visualized in female kidney recipients. 
However, only 2–2.5% of the intravenously injected MSCs showed engraftment (Morigi et al., 
2004).  
The study of Herrera et al. (2007) demonstrated the role of CD44 and its major ligand, 
hyaluronic acid, in the trafficking of intravenously injected MSC to localize in kidney 
parenchyma in the glycerol-induced mouse model of acute renal failure (ARF) (Herrera et al., 
2007). The direct engraftment of exogenously administered, and transdifferentiating MSCs was 
not the predominant mechanism in which MSCs enhance renal repair. MSCs could elicit kidney 
repair through paracrine and/or endocrine mechanisms, where they release trophic growth factors 
that modulate the immune response and consequently mediate repair. The ability of MSCs to 
inhibit the release of pro-inflammatory cytokines and secrete a variety of trophic growth factors 
that promote angiogenesis, mitogenesis, and proliferation whilst reducing apoptosis may 
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collectively mediate the protective and regenerative effects in the kidney of laboratory rodents 
(Wise and Ricardo, 2012).  
In a rat model of acute kidney injury (AKI) established by unilateral renal ischemia 
before intravenous transplantation of UMCs, there was no evidence of UMCs engrafted at the 
ischemic areas. UMCs contributed to tubular EMT delay and the alleviation of renal fibrosis. 
 Induction of native and foreign HGF synthesis in damaged tubular epithelial cells at the 
initial stage of AKI leads to recovery of the disturbed balance of HGF/TGF-β1 during scar 
formation (Du et al., 2013). In a pilot clinical study of chronic kidney disease, two intravenous 
transplantations 1 week apart of ~1 million MSCs/kg body showed significant difference 
between each of serum creatinine and creatinine clearance levels before and after MSC injection 
at 1, 3, and 6 months after infusion (El-Ansary et al., 2012b). 
 Bone 
Because of the lack of an adequate supply of autologous bone grafts and the unsuitability 
of allografts, there has been some motivation to use MSCs to encourage repair. Studies on 
murine models show promising results, especially for bone repair and metabolic bone disorders. 
In vitro expanded autologous BM-MSCs loaded on a 3-dimensional construct of porous 
hydroxyapatite scaffolds was used to cure bone nonunion and diaphyseal defects and resulted in 
good integration of implant (Undale et al., 2009). Complete fusion between the implant and the 
host bone occurred 5-7 months post operation. Follow up in patients for 6-7 years after surgery 
showed the good integration of implants maintained. Angiographic evaluation of implants after 
seven years showed vascularisation of the grafted zone, which is believed to be vital for the 
survival and future stability of the graft (Marcacci et al., 2007).  
Autologous BM-MSCs derived from bone marrow were cultured with beta-tricalcium 
phosphate (β-TCP) ceramics granules before implanting into the cavity that remained after 
curettage of necrotic bone and ,finally, a free vascularized fibula was grafted. Osteonecrosis did 
not progress any further and early bone regeneration was observed (Kawate et al., 2006).  
SDF-1 and its receptor CXCR4 have been shown to act as a potential homing signal for 
MSCs in bone healing. High expression of SDF-1 protein was observed in the periosteum of the 
live graft. New bone formation was inhibited by the administration of anti–SDF-1 antibody or 
TF14016 (Kitaori et al., 2009).  
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Osteogenesis imperfecta (OI) is a connective tissue disorder disease that osteoblasts 
produce defective type I collagen. This genetic disorder is characterized by bone fragility and 
other evidence of connective tissue malfunction. When MSCs from wild-type mice were infused 
into transgenic mice that had a phenotype of fragile bones resembling OI, the MSCs served as a 
source for continual renewal of cells in a number of nonhematopoietic tissues. Donor cells 
accounted for 4–19% of the fibroblasts or fibroblast-like cells obtained in primary cultures of the 
lung, calvaria, cartilage, long bone, tail, and skin (Pereira et al., 1998). Allogeneic bone marrow 
transplant in 3 children with OI showed osteoblast engraftment, that was nearly 2.0% donor 
cells. Histologic changes indicated new bone formation and increased total body bone mineral 
content (Horwitz et al., 1999). Horwitz et al. treated six children suffering from OI by systemic 
infusion of MSCs for bone regeneration. Five children showed acceleration of bone growth 
compared with matched unaffected children (Horwitz et al., 2002). 
 UMCs for lung injury 
UMCs transplanted systemically into mouse model of bleomycin-induced lung injury 
showed engraftment at the fibrosis and inflammation areas of lung. Transplantation of UMCs 
reduced inflammation and secreted inflammatory cytokines. Anti-fibrotic effects of engrafted 
UMCs likely relate to reduction of secreted TGF-β, an activator of fibrosis through a Smad 
pathway (Wang et al., 2005). Moreover, UMCs increased matrix metalloproteinase-2 levels and 
reduced their endogenous inhibitors favoring a pro-degradative milieu following collagen 
deposition whereas transplanted fibroblasts did not have these properties (Moodley et al., 2009). 
 Antibacterial effects 
MSCs possess intrinsic antimicrobial properties on the bacterial growth of Gram-negative 
and positive bacteria. Krasnodembskaya et al. (2010) reported MSCs derived from human bone 
marrow and their conditioned medium inhibited the growth of Escherichia coli, Pseudomonas 
aeruginosa and Staphylococcus aureus bacteria. Major antimicrobial peptide secreted from 
MSCs after induction by bacteria was the human cathelicidin antimicrobial peptide, hCAP-
18/LL-37. In a mouse model of E. coli pneumonia, intratracheal administration of MSCs reduced 
bacterial growth in the lung homogenates and in the bronchoalveolar lavage (BAL) fluid 
indicating rapid bacterial clearance (Krasnodembskaya et al., 2010). LL-37 peptide secreted from 
MSCs not only had antimicrobial potential but could recruit migration of MSCs into the 
36 
 
damaged tissues via the formyl peptide receptor, FPLR-1 (Coffelt et al., 2009). Toll-like receptor 
(TLR4) expressed on the MSC surface has been reported to bind with LL-37 through a 
concentration gradient for activation of MSCs migration toward the source of infection and 
immunomodulatory properties (Tomchuck et al., 2008). A study of Meisel et al. (2011) showed 
that, on stimulation with inflammatory cytokines, IDO-positive human MSCs exhibited a cell 
autonomous, broad-spectrum antimicrobial effector function directed against clinically relevant 
bacteria, protozoa, parasite and virus. IDO expressed by induced MSCs played a role by 
depleting tryptophan, amino acid, required for microbial growth (Meisel et al., 2011) 
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Chapter 2 - Characterization of Pig Umbilical Cord Matrix Stem 
Cells (PUCs) 
 Introduction 
Mesenchymal stem cells (MSCs) are plastic-adherent and have self-renewal and multi-
potential differentiation properties, They express the cell surface markers CD105, CD73 and 
CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR 
(Dominici et al., 2006). A summary of adult human MSCs surface markers from published 
literature shows that the most commonly detected markers are CD13, CD29, CD44, CD49e, 
CD51, CD 54, CD59, CD71, CD73, CD90, CD105, CD106, CD146 and CD 166. The most 
frequently markers that are reported as not detected are CD31, CD34, CD14, CD45, CD11b, 
CD49d, CD106, CD10 and CD31 (Pa et al., 2011). Adult human MSCs are expected to 
differentiate in vitro into the three mesodermal lineages: osteogenesis, chondrogenesis and 
adipogenesis (Kern et al., 2006; Maurer et al., 2011).  
MSCs can be derived from both of adult and fetal tissues including bone marrow (Tropel 
et al., 2004), adipose tissue (Taghi et al., 2012), dental pulp (Perry et al., 2008), synovial 
membrane (De Bari et al., 2001), skin (Orciani and Di Primio, 2013), peripheral blood (Cao et 
al., 2005), amniotic fluid (De Coppi et al., 2007), umbilical cord blood and placenta (Barlow et 
al., 2008).   The quantitatively largest source is Wharton’s jelly (WJ) of the umbilical cord, a 
source first described by Mitchell et al. (2003), and reviewed recently by Taghizadeh et al. 
(2011) and Longo et al. (2012). The in vitro proliferation kinetics of MSCs is important for their 
applications in cell therapy and tissue engineering. Compared to adult MSCs, MSCs derived 
from fetal tissues have a higher proliferation capacity (Lee et al., 2006; Baksh et al., 2007; 
Ramkisoensing et al., 2011) and with longer maintenance of the undifferentiated condition in 
vitro (Sabapathy et al., 2012) and greater engraftment capacity (Brooke et al., 2008). 
MSCs are isolated from WJ the cushioning tissue of umbilical cords. Umbilical cords are 
discarded and isolation of umbilical cord (UC) MSCs from the WJ matrix is low cost and 
without ethical issues. UC cells are plastic-adherent and display a high frequency of colony 
formation (CFU-F) when plated on plastic (Karahuseyinoglu et al., 2007). The cells from human 
cords express stromal markers (CD29, CD44, CD73, CD90, CD105 and CD106), but they are 
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negative for hematopoietic markers (CD34 and CD45). In addition, they are capable of 
mesodermal differentiation (Li et al., 2012). 
Porcine umbilical cords matrix stem cells (PUCs) are derived from porcine umbilical 
cords. Because pig physiology, anatomy, and genetics are closely related to humans, PUCs 
provide a good biological model for studies such of cell-based therapy and tissue engineering. 
Pigs are also an important agricultural species and understanding of their biology important in its 
own right. The objectives of our investigations are to characterize the PUCs derived from 
porcine WJ explants for their immunophenotypes and mesodermal differentiation. Additionally, 
growth kinetics of PUCs was investigated to derive estimates of population doubling time (PDT) 
and gain insights into potential ex vivo expansion of PUCs. 
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Materials and Methods 
 PUC isolation 
Umbilical cords were collected from newborn pigs at the Kansas State University Swine 
Research and Teaching Center. Umbilical cords were collected aseptically at birth and placed in 
storage and transport buffer (STB) consisting of phosphate buffered saline (PBS) supplemented 
with antimycotic/antibiotic reagent (Gibco, Grand Island, NY, 1:100). The cords were stored at 
5º C in STB up to 24 h before WJ was harvested for cell isolation. In the laboratory, each 
umbilical cord was rinsed with fresh STB and placed in a sterile Petri dish. The cords were 
opened longitudinally using aseptic techniques.  The vein and arteries were removed using 
hemostats. WJ was scraped from cords with a sterile, medical-grade blade and placed in Petri 
dishes (150 cm
2
) where it was cut into pieces (approximately 1-3 mm
3
).  The WJ pieces 
(explants) were allowed to air-dry for 10 minutes to increase attachment and then complete 
growth medium added.   The growth medium consisted of  high-glucose Dulbecco’s Minimum 
Essential Medium with HEPES (GlutaMAX™-DMEM-HEPES, Invitrogen, Grand Island, NY) 
supplemented with fetal bovine serum (20% FBS, Invitrogen), Normocin (100 µg/ml, 
Invitrogen), Gentamicin Reagent Solution (25 µg/ml Gentamicin, Invitrogen) and 2-
mercaptoethanol (55 µmol/ml, Sigma). Culture dishes were incubated at 38.5°C with 5% CO2 
and saturated humidity. The tissues explants were removed from culture when PUCs migrated 
out from WJ explants and attached on the dish after incubation for 5-7 days. PUCs were 
harvested by dissociation with 0.1% trypsin (Gibco) + 1.0 mM EDTA in PBS. Harvested cells 
were re-suspended in Recovery Cell Culture Freezing Medium (Gibco) and cryopreserved in 
liquid nitrogen. 
 Mesodermal differentiation potential of PUCs 
The adipogenic potential of PUCs was tested using the StemPro® Adipogenesis 
Differentiation Kit (Gibco) containing StemPro® Adipocyte Differentiation Basal Medium and 
StemPro® Adipogenesis Supplement. Early PUCs (P3) were plated in tissue culture flasks 
(1x10
4
cells/cm
2
). They were cultured in complete growth medium at 38.5°C in a humidified 
atmosphere of 5% CO2 until they reached 80-90% confluence. The complete growth medium 
was replaced by adipogenesis differentiation medium prepared according to the kit instructions. 
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PUCs were cultured continuously under the differentiation medium for 21 days by replacing new 
differentiation medium every 3 days.  
After 21 days, cultured PUCs were washed 3 times with PBS and fixed with 4% 
paraformaldehyde solution for 30 minutes at room temperature. The fixed cells were rinsed twice 
with PBS and LipidTOX™ Red (diluted 1:100) (Invitrogen) added to dye the neutral lipid 
droplets red (fluorescence excitation/emission maxima as 577/609 nm) and incubated for 30 
minutes at room temperature. Cell nuclei were counterstained with green-fluorescent nucleic 
stain, Syto®16 (Invitrogen) (0.05 µM) (maximum excitation/emission 448/518) for 8 minutes at 
room temperature. Cells were mounted on slides with cover slips using glycerol solution (Fisher 
Bioreagents®). Intracellular stained neutral lipid droplets were observed under an inverted Zeiss 
LSM 700 confocal microscope (LSM 700, Carl Zeiss). The 40x/1.30 Oil M27 EC Plan-Neofluar 
objective lens with a pinhole opened 30 µm was used to visualize within a field of view of 266.5 
× 266.5 μm. Image size and dynamic range were 1024x1024 and 8 bit. Scanning speed number, 
mode of scanning and average number of signal/noise ratio were 6, line mode and 4, 
respectively. Sequential excitation was at 2% of 488 nm and 2% of 555 was provided by argon 
and helium-neon gas lasers. Emission filters BP 520-580 nm and LP 630 nm were used for 
collecting green and red in channels one and two with the master gain of each channel as 428 and 
360, respectively. After sequential excitation, green and red fluorescent images of the same cell 
were saved and analyzed by Zeiss Zen 2010 software.  
To determine an adipogenic potential, PUCs were incubated in adipogenic differentiation 
medium for 21 days then harvested (0.1% trypsin + 1.0 mM EDTA in PBS) and washed 3 times 
with PBS. Cells were fixed (4% paraformaldehyde for 30 minutes at room temperature) then 
washed twice with PBS to remove residual paraformaldehyde. Fixed cells were stained with 
LipidTOX™ Red (diluted 1:100) (Invitrogen) for 30 minutes at room temperature and they were 
analyzed for the emission of red fluorescence through the PM3 channel of a microcapillary 
cytometer (Guava EasyCyte Plus, Millipore). PUCs cultured in complete growth medium were 
stained by LipidTOX™ Red and used as a negative control. 
For chondrogenic differentiation, PUCs were cultured in chondrogenesis differentiation 
medium (StemPro® Chondrogenesis Differentiation Kit; Gibco®) according to the kit 
instructions. PUCs suspended in complete growth medium at 1.6 x 10
7
 viable cells/ml were 
seeded in a 5 µl droplet in the center of wells of a multi-well plate to generate micromass 
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cultures. After cultivating micromass cultures for 6 h at 38.5°C in a humidified atmosphere of 
5% CO2, 3 ml of warmed chondrogenesis differentiation medium was added and the plate was 
incubated for 21 days at 38.5°C in a humidified atmosphere of 5% CO2. Differentiation medium 
was removed and the cells were washed 3 times with PBS. Then, cells were fixed with 4% 
paraformaldehyde solution for 30 minutes at room temperature, rinsed twice with PBS and 
stained 30 minutes with 1% (w/v) Alcian Blue solution prepared in 0.1 N HCl. The stained cells 
were rinsed 3 times with 0.1N HCl and distilled water added to neutralize the acidity. The blue 
color-stained cells indicated the synthesis of proteoglycans by chondrocytes. 
Osteogenic differentiation of PUCs was investigated using the StemPro® Osteogenesis 
Differentiation Kit (Gibco). Early passage (P3) PUCs were seeded in culture wells at 
5x10
3
cells/cm
2
 and cultured in complete growth medium at 38.5°C until they reached 80-90% 
confluence. The medium was replaced with pre-warmed osteogenesis differentiation medium 
prepared according to the kit instructions. PUCs were cultured continuously under the 
differentiation medium for 21 days with replacement every 3 days. After 21 days, the PUCs were 
washed 3 times with PBS, fixed (4% paraformaldehyde for 30 minutes at room temperature). 
The fixed cells were rinsed twice with PBS before 2% (w/v) Alizarin Red S solution (pH 4.2) 
prepared in distilled water) was added and incubated 3 minutes. The stained cells were rinsed 3 
times with distilled water and visualized under a light microscope. Cultured cells undergoing 
osteogenesis differentiation showed increased mineral deposition and were stained red color by 
Alizarin Red S dye. 
 Cell surface marker staining and flow cytometry 
Early passages of PUCs were analyzed to determine surface phenotype. Mouse 
monoclonal antibodies to porcine CD31 (LCI-4): IgG1- RPE, CD45 (K252-1E4): IgG1-FITC 
and SLA class II DR (2E9/13): IgG2b-FITC (AbD Serotec, Bio-Rad, Hercules, CA), porcine 
CD105 (MEM-229): IgG2a-FITC and CD90 (5E10): IgG1-FITC (Abcam, Cambridge, MA) and 
porcine CD44 (MEM-263): IgG1-FITC (Thermo Scientific, Middletown, VA). All isotype 
control antibodies derived from mice (IgG1-FITC, IgG1-RPE, IgG2a-FITC and IgG2b-FITC) 
were purchased from Invitrogen (Carlsbad, CA). Cultures were washed twice with PBS, and 
cells detached by enzymatic treatment (0.05% trypsin/EDTA in PBS) for 7 minutes at room 
temperature. Culture medium was added to inactivate trypsin and cells were washed twice with 
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PBS before adjusting to 1 × 10
7
 cells /ml in PBS. Cell suspensions (100 µl) were incubated with 
5-10 μl of antibodies or isotype controls (to provide a final concentration of 3µg/ml) for 45 
minutes at 4°C in the dark. Fluorescence emission of cells was analyzed using a microcapillary 
cytometer (Guava EasyCyte Plus, Millipore). Nonspecific background was evaluated by parallel 
staining with isotype-matched IgG1-FITC, IgG1-RPE, IgG2a-FITC and IgG2b-FITC. The cell 
population was gated separately from the cell debris using a side scatter/forward scatter dot plot 
and, then was applied to the histograms for green, yellow, and red fluorescence. The number and 
percent positive cells was generated by CytosoftTM software, Guava ExpressPro assay 
(Millipore). 
 In vitro doubling time for PUCs 
PUCs (P3) were plated (10
4
 cells/cm
2
) in a 75 cm
2
 tissue culture flask and cultured with 
complete culture medium until >90% confluent. PUCs were synchronized to the resting phase, 
washed 3 times with PBS and were incubated with StemPro® basal medium with no serum 
(Invitrogen) for 6 days with medium replacement every 2 days. Cells cycle stage was determined 
by Guava® Cell Cycle Reagent (Millipore) and microcapillary cytometer (Guava EasyCyte Plus, 
Millipore). Briefly, harvested PUCs (1x10
5
 cells) were washed 3 times with PBS and fixed in 10 
ml of ice-cold 70% ethanol 1-12 hours prior to staining. Fixed cells were centrifuged and 
supernatant was discarded. Then, cells were washed 1 time with PBS for 1 minute at room 
temperature. The washed cells were centrifuged and the supernatant was removed. Ethanol-fixed 
cells were resuspended in 200 µl Guava® Cell Cycle Reagent and incubated at room temperature 
for 30 minutes with shielding from light. The stained cells were transferred to a 1.5 ml 
microcentrifuge tube before acquiring the data from the PM2 (red) channel. To generate growth 
curves, PUCs in resting phase were plated (10
4 
cells/cm
2
) in 6-well plate. The viable cell 
numbers were determined at 12, 24, 36, 48, 60, 72, 84, 96 and 108 hours after plating. 
Determination of cells number was performed in triplicate. The cell doubling time of PUCs was 
calculated using the Patterson formula: Td = Tlog2/logN1-logN0 (Td = doubling time, T = log 
phase time, N1 = cell number at the end of the log phase, N0 = cell number at the beginning of 
the log phase). 
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 Results 
 PUCs isolation 
Wharton’s jelly explants attached to the dish within 1 day after plating. Cells were seen 
migrating from the explants after culturing 2-3 days (Fig 2.1A). The migrating cells had a 
heterogeneous shape, including fibroblast-like cells with short and long processes and small 
round cells with a highly reflective appearance (Fig 2.1B). Cells grew to 80% or more confluent 
in 7-10 days and the interval between the explant plating and the first passage was about 2 
weeks. Approximately, 1.2 x 10
7
 cells were harvested at first passage with viability greater than 
90%. 
 Mesodermal differentiation potential of PUCs 
After 14-21 days, PUCs cultured in the differentiation induction media demonstrated 
adipogenic, osteogenic and chondrogenic differentiation as assessed by appropriate staining. For 
adipogenic supplementation, differentiation was apparent after 3 weeks of induction. 
Morphologically PUCs changed from fibroblastic to spherical and intracellular lipid droplets 
appeared. The accumulated lipid vacuoles were visualized by LipidTOX™ Red neutral lipid 
stain (Figure 2.2A-C). The non-treated PUCs cultured in complete growth medium showed no 
lipid droplets or staining with with LipidTOX™ Red (Fig 2.2D). Flow cytometry revealed 5.84% 
of PUCs displayed staining indicative of adipogenesis (Figure 2.3).  
Osteogenic differentiation conditions for 21 days resulted in matrix calcification as 
identified by Alizarin red staining. The dye-calcium complexes with extracellular calcium 
deposits exhibited a bright orange-red color (Figure 2.4). 
Chondrogenic differentiation potential of PUCs in chondrogenesis differentiation 
medium for 21days resulted in cell pellets within 3 days and the pellet size increased over a 
period of 2 to 3 weeks. After 3 weeks, pellets stained with Alcian blue dye were positive 
indicated the presence of sulfated proteoglycan, a matrix component of mature chondrocyte 
cultures (Figure 2.5). 
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 Immunophenotypic analysis of PUCs 
Flow cytometry results showed that early passage of PUCs (P5) shared most of their 
immunophenotype with mesenchymal stem cells by uniformly positive expression (> 90%) for 
stromal markers (CD44, CD90 and CD105), but lack of expression (< 2%) for hematopoietic 
markers (CD45, CD31 and HLA-DR) as shown in Table2.1 and Figure2.6. 
 In vitro doubling time for PUCs 
PUCs were culture for 5 days in 2% FBS culture medium to induce cell cycle 
synchronisation at resting (G0/G1) phase before determination of cell doubling time. Almost all 
(92.5%) PUCs were at G0/G1 phase after starvation for 6 days (Fig 2.7 and Table 2.2). The 
viability of synchronized PUCs was 77.1%. Complete growth medium containing 20% FBS was 
added to the cells and PUCs were harvested at 12, 24, 36, 48, 60, 72, 84, 96 and 108 hours after 
plating (Table 2.3). Viability of harvested PUCs was between 88-93%. The growth curves 
displayed an initial lag phase of 24 hours, a log phase at exponential rate from 24 to 84 hours, 
and a plateau phase. According to the Patterson formula, the doubling time in the log phase of 
PUCs was 13.8 hours (Fig 2.8). 
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 Discussion 
Migrating cells from WJ explants initially contained a heterogeneous population of cells 
with fibloblast-like and small round cell morphologies. They were observed around the explants 
after incubation for approximately 5 days. Similarly, human umbilical cord matrix stem cells 
isolated by the enzymatic method comprised a heterogeneous population, mesenchymal-like 
cells and small round cells with a high nuclear to cytoplasm ratio (Weiss et al., 2006). The small 
round cell population exhibited rapid proliferation and low population doubling time (PDT) 
(Christodoulou et al., 2013). Also, the subpopulation of high reflective small round cells was 
found in isolated bone marrow mesenchymal stem cells and they were called the rapid self-
renewal (RS) cells. They are reportedly the precursor of the mature fibroblast-like cells and 
exhibited multilineage differentiation potential (Colter et al., 2000; Colter et al., 2001). 
Cells isolated from WJ derived from human (Abu Kasim et al., 2012), canine (Lee et al., 
2013), bovine (Cardoso et al., 2012), equine (Hoynowski et al., 2007), and rat (Ganta et al., 
2009) umbilical cords are positive for MSCs markers (CD44, CD90, CD73 and CD105) and lack 
markers for the hematopoietic lineage (CD34 and CD45). Cells isolated from porcine WJ cell are 
consistent with this pattern. Greater than 90% of early passage PUCs expressed CD90, CD44 and 
CD105, but not CD 31, CD45 and SLA-DR. We did not evaluate CD 73 and CD34, two of the 
indicated standard CD markers for MSCs, because we did not have antibodies for these porcine 
antigens. Moreover, monoclonal antibodies against human CD73 and CD34 do not cross react 
with porcine CD73 and CD34 (Noort et al., 2012; Rozemuller et al., 2010). Monoclonal antibody 
against CD31 antigen specific to platelet, leukocytes and endothelial cells and used to 
characterize MSCs (Peister et al., 2004) was performed to characterize cells isolated from 
porcine Wharton’s jelly instead of employing CD34. 
Mesenchymal stem cells isolated from WJ of miniature pigs were positive for CD44, 
CD90, SLA class I and negative for CD31, CD45, SLA class II-DR, SLA class II-DQ (Cho et 
al., 2008; Kang et al., 2013). Using an explant isolation method, MSCs isolated from WJ of 
postnatal miniature pig showed expression of CD29, CD44 and CD90 (98%, 83.3% and 84.7%, 
respectively). Additionally, they were negative for CD45 (0%) and had low expression of SLA 
class II-DR (4%) (Kang et al., 2013).  
73 
 
Expression levels of CD markers of MSCs isolated from the same source may differ due 
to the isolation method, the procedure of fixation and staining, the concentration of monoclonal 
antibodies, the passage number or other factors. 
Here, we demonstrated that cells isolated from porcine WJ contained MSCs capable of 
mesodermal lineage differentiation. Adipocyte, osteocyte, and chondrocyte differentiation in 
vitro was shown. Under adipogenic differentiation conditions, PUCs changed into a cuboidal 
shape and contained tiny intracellular lipid droplets. The multilocular cells could be considered 
as early adipocytes and the spindle shape cells in the absence of detectable lipid droplets have 
been identified as preadipocytes (Zhang et al., 2012). MSCs isolated from bone marrow showed 
high potential for adipogenic differentiation in that they formed large homogeneous intracellular 
lipid droplets after culturing in adipogenic differentiation medium (Sekiya et al., 2004). Sekiya et 
al. (2004) and Chang et al. (2006) have reported that MSCs isolated from umbilical cords-related 
tissues expressed lower potency of adipogenic differentiation than bone marrow mesenchymal 
stem cells. Flow cytometry illustrated that low numbers of WJ-derived cells were able to 
differentiate to adipocytes. This could be because the improper ingredients in adipogenic 
induction medium were not optimal (Scott et al., 2011), inadequate incubation time or an 
unsuitable oxygenic condition (Valorani et al., 2010). It could also be that the more primitive 
WJ-cells are less capable of adipogenesis (Ragni et al., 2013). 
For kinetic analyses of cell cycle progression it is desirable to synchronize the cells in 
G1/G0. This can be achieved by growing the culture to confluence followed by serum 
deprivation (Schorl and Sedivy, 2007). Perinatal MSCs derived from WJ have shorter doubling 
times than adult MSCs derived from adipose tissues (Christodoulou et al., 2013) and there was 
no difference of proliferation kinetics of WJ-derived MSCs cultured in passage 1 and 7 with lag 
and log phase as 72 and 48 hours respectively (Zhou et al., 2011). Qiao et al. (2008) have shown 
that early passage human umbilical cord matrix stem cells had population doubling time (PDT) 
of 26 hours and it was as fast as that of human bone marrow MSCs (Qiao et al., 2008). 
Here, the growth curve of early passage of cells isolated from porcine WJ was generated 
after synchronizing cells into resting (G0/G1) phase. According to the growth cure, proliferating 
cells exhibited a lag phase, a log phase and doubling time (24, 60 and 13.8 hours respectively). 
The doubling time is considerably shorter than reported for other MSCs including WJ cells. A 
shorter doubling time is an advantage for expanding WJ cells for use in experiments and 
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therapies. Understanding the growth kinetic of MSCs after synchronizing cells into the resting 
phase may also be useful information for increasing gene transfer efficiency using viral 
transduction. Viruses have specific transduction character into different host cell stages. High 
efficiency for retroviral transduction was observed in cells resting in G0/G1 (Chen et al., 2012). 
However, adeno-associated virus preferentially transduced proliferating cells (Russell et al., 
1994).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
75 
 
 
References 
Abu Kasim, N. H., V. Govindasamy, N. Gnanasegaran, S. Musa, P. J. Pradeep, T. C. Srijaya et 
 al. 2012. Unique molecular signatures influencing the biological function and fate of 
 post-natal stem cells isolated from different sources. J. Tissue Eng. Regen. Med.  
Baksh, D., R. Yao, and R. S. Tuan. 2007. Comparison of proliferative and multilineage 
 differentiation potential of human mesenchymal stem cells derived from umbilical cord 
 and bone marrow. Stem Cells. 25(6): 1384-1392.  
Barlow, S., G. Brooke, K. Chatterjee, G. Price, R. Pelekanos, T. Rossetti et al. 2008. Comparison 
 of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem 
 Cells Dev. 17(6): 1095-1107. 
Brooke, G., H. Tong, J. P. Levesque, and K. Atkinson. 2008. Molecular trafficking mechanisms 
 of multipotent mesenchymal stem cells derived from human bone marrow and placenta. 
 Stem Cells Dev. 17(5): 929-940.  
Cao, C., Y. Dong, and Y. Dong. 2005. Study on culture and in vitro osteogenesis of blood-
 derived human mesenchymal stem cells. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 
 19(8): 642-647.   
Cardoso, T. C., H. F. Ferrari, A. F. Garcia, J. B. Novais, C. Silva-Frade, M. C. Ferrarezi et al. 
 2012. Isolation and characterization of wharton's jelly-derived multipotent mesenchymal 
 stromal cells obtained from bovine umbilical cord and maintained in a defined serum-free 
 three-dimensional system. BMC Biotechnol. 12: 18-6750-12-18. 
Chang, Y. J., D. T. Shih, C. P. Tseng, T. B. Hsieh, D. C. Lee, and S. M. Hwang. 2006. Disparate 
 mesenchyme-lineage tendencies in mesenchymal stem cells from human bone marrow 
 and umbilical cord blood. Stem Cells. 24(3): 679-685.  
Chen, M., J. Huang, X. Yang, B. Liu, W. Zhang, L. Huang et al. 2012. Serum starvation induced 
 cell cycle synchronization facilitates human somatic cells reprogramming. PLoS One. 
 7(4): e28203.   
Cho, P. S., D. J. Messina, E. L. Hirsh, N. Chi, S. N. Goldman, D. P. Lo et al. 2008b. 
 Immunogenicity of umbilical cord tissue derived cells. Blood. 111(1): 430-438. 
76 
 
Christodoulou, I., F. N. Kolisis, D. Papaevangeliou, and V. Zoumpourlis. 2013. Comparative 
 evaluation of human mesenchymal stem cells of fetal (wharton's jelly) and adult (adipose 
 tissue) origin during prolonged in vitro expansion: Considerations for cytotherapy. Stem 
 Cells Int. 2013: 246134.  
Colter, D. C., R. Class, C. M. DiGirolamo, and D. J. Prockop. 2000. Rapid expansion of 
 recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc. 
 Natl. Acad. Sci. U. S. A. 97(7): 3213-3218.  
Colter, D. C., I. Sekiya, and D. J. Prockop. 2001. Identification of a subpopulation of rapidly 
 self-renewing and multipotential adult stem cells in colonies of human marrow stromal 
 cells. Proc. Natl. Acad. Sci. U. S. A. 98(14): 7841-7845. 
De Bari, C., F. Dell'Accio, P. Tylzanowski, and F. P. Luyten. 2001. Multipotent mesenchymal 
 stem cells from adult human synovial membrane. Arthritis Rheum. 44(8): 1928-1942.  
De Coppi, P., G. Bartsch Jr, M. M. Siddiqui, T. Xu, C. C. Santos, L. Perin et al. 2007. Isolation 
 of amniotic stem cell lines with potential for therapy. Nat. Biotechnol. 25(1): 100-106.   
Dominici, M., K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, D. Krause et al. 2006. 
 Minimal criteria for defining multipotent mesenchymal stromal cells. the international 
 society for cellular therapy position statement. Cytotherapy. 8(4): 315-317.  
Ganta, C., D. Chiyo, R. Ayuzawa, R. Rachakatla, M. Pyle, G. Andrews et al. 2009. Rat umbilical 
 cord stem cells completely abolish rat mammary carcinomas with no evidence of 
 metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res. 69(5): 1815-
 1820.  
Hoynowski, S. M., M. M. Fry, B. M. Gardner, M. T. Leming, J. R. Tucker, L. Black et al. 2007. 
 Characterization and differentiation of equine umbilical cord-derived matrix cells. 
 Biochem. Biophys. Res. Commun. 362(2): 347-353.  
Kang, E. J., Y. H. Lee, M. J. Kim, Y. M. Lee, B. M. Kumar, B. G. Jeon et al. 2013. 
 Transplantation of porcine umbilical cord matrix mesenchymal stem cells in a mouse 
 model of parkinson's disease. J. Tissue Eng. Regen. Med. 7(3): 169-182.  
Karahuseyinoglu, S., O. Cinar, E. Kilic, F. Kara, G. G. Akay, D. O. Demiralp et al. 2007. 
 Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem 
 Cells. 25(2): 319-331.  
77 
 
Kern, S., H. Eichler, J. Stoeve, H. Kluter, and K. Bieback. 2006. Comparative analysis of 
 mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. 
 Stem Cells. 24(5): 1294-1301.  
Lee, C. C., F. Ye, and A. F. Tarantal. 2006. Comparison of growth and differentiation of fetal 
 and adult rhesus monkey mesenchymal stem cells. Stem Cells Dev. 15(2): 209-220.  
Lee, K. S., J. J. Nah, B. C. Lee, H. T. Lee, H. S. Lee, B. J. So et al. 2013. Maintenance and 
 characterization of multipotent mesenchymal stem cells isolated from canine umbilical 
 cord matrix by collagenase digestion. Res. Vet. Sci. 94(1): 144-151.  
Li, J., D. Li, X. Liu, S. Tang, and F. Wei. 2012. Human umbilical cord mesenchymal stem cells 
 reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J. 
 Inflamm. (Lond). 9(1): 33-9255-9-33. 
Longo, U. G., M. Loppini, A. Berton, L. La Verde, W. S. Khan, and V. Denaro. 2012. Stem cells 
 from umbilical cord and placenta for musculoskeletal tissue engineering. Curr. Stem Cell. 
 Res. Ther. 7(4): 272-281. 
Maurer, M. H. 2011. Proteomic definitions of mesenchymal stem cells. Stem Cells Int. 2011: 
704256.   
Mitchell, K. E., M. L. Weiss, B. M. Mitchell, P. Martin, D. Davis, L. Morales et al. 2003. Matrix 
 cells from wharton's jelly form neurons and glia. Stem Cells. 21(1): 50-60  
Noort, W. A., M. I. Oerlemans, H. Rozemuller, D. Feyen, S. Jaksani, D. Stecher et al. 2012. 
 Human versus porcine mesenchymal stromal cells: Phenotype, differentiation potential, 
 immunomodulation and cardiac improvement after transplantation. J. Cell. Mol. Med. 
 16(8): 1827-1839. 
Orciani, M., and R. Di Primio. 2013. Skin-derived mesenchymal stem cells: Isolation, culture, 
 and characterization. Methods Mol. Biol. 989: 275-283.  
Pa, M., H. S, M. R, G. M, and S. K. W. 2011. Adult mesenchymal stem cells and cell surface 
 characterization - a systematic review of the literature. Open Orthop. J. 5(Suppl 2): 253-
 260. 
 Peister, A., J. A. Mellad, B. L. Larson, B. M. Hall, L. F. Gibson, and D. J. Prockop. 2004. Adult 
 stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary 
 in surface epitopes, rates of proliferation, and differentiation potential. Blood. 103(5): 
 1662-1668. 
78 
 
Perry, B. C., D. Zhou, X. Wu, F. C. Yang, M. A. Byers, T. M. Chu et al. 2008. Collection, 
 cryopreservation, and characterization of human dental pulp-derived mesenchymal stem 
 cells for banking and clinical use. Tissue Eng. Part C. Methods. 14(2): 149-156.  
Qiao, C., W. Xu, W. Zhu, J. Hu, H. Qian, Q. Yin et al. 2008. Human mesenchymal stem cells 
 isolated from the umbilical cord. Cell Biol. Int. 32(1): 8-15. 
Ragni, E., M. Vigano, V. Parazzi, T. Montemurro, E. Montelatici, C. Lavazza, S. Budelli, A.  
Vecchini, P. Rebulla, R. Giordano and L. Lazzari. 2013. Adipogenic potential in human 
mesenchymal stem cells strictly depends on adult or foetal tissue harvest. Int J Biochem 
Cell Biol. 45(11): 2456-2466. 
Ramkisoensing, A. A., D. A. Pijnappels, S. F. Askar, R. Passier, J. Swildens, M. J. Goumans et 
 al. 2011. Human embryonic and fetal mesenchymal stem cells differentiate toward three 
 different cardiac lineages in contrast to their adult counterparts. PLoS One. 6(9): e24164.   
Rozemuller, H., H. J. Prins, B. Naaijkens, J. Staal, H. J. Buhring, and A. C. Martens. 2010. 
 Prospective isolation of mesenchymal stem cells from multiple mammalian species using 
 cross-reacting anti-human monoclonal antibodies. Stem Cells Dev. 19(12): 1911-1921. 
Russell, D. W., A. D. Miller and I. E. Alexander. 1994. Adeno-associated virus vectors  
preferentially transduce cells in S phase. Proc Natl Acad Sci U S A. 91(19): 8915-8519. 
Sabapathy, V., S. Ravi, V. Srivastava, A. Srivastava, and S. Kumar. 2012. Long-term cultured 
 human term placenta-derived mesenchymal stem cells of maternal origin displays 
 plasticity. Stem Cells Int. 2012: 174328. 
Schorl, C., and J. M. Sedivy. 2007. Analysis of cell cycle phases and progression in cultured 
 mammalian cells. Methods. 41(2): 143-150.  
Scott, M. A., V. T. Nguyen, B. Levi, and A. W. James. 2011. Current methods of  adipogenic 
 differentiation of mesenchymal stem cells. Stem Cells Dev. 20(10): 1793- 1804.  
Sekiya, I., B. L. Larson, J. T. Vuoristo, J. G. Cui, and D. J. Prockop. 2004. Adipogenic 
 differentiation of human adult stem cells from bone marrow stroma (MSCs). J. Bone 
 Miner. Res. 19(2): 256-264.  
Taghi, G. M., H. Ghasem Kashani Maryam, L. Taghi, H. Leili, and M. Leyla. 2012. 
 Characterization of in vitro cultured bone marrow and adipose tissue-derived 
 mesenchymal stem cells and their ability to express neurotrophic factors. Cell Biol. Int. 
 36(12): 1239-1249.  
79 
 
Taghizadeh, R. R., K. J. Cetrulo, and C. L. Cetrulo. 2011. Wharton's jelly stem cells: Future 
 clinical applications. Placenta. 32 Suppl 4: S311-5.  
Tropel, P., D. Noel, N. Platet, P. Legrand, A. L. Benabid, and F. Berger. 2004. Isolation and 
 characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp. Cell 
 Res. 295(2): 395-406. 
Valorani, M. G., A. Germani, W. R. Otto, L. Harper, A. Biddle, C. P. Khoo et al. 2010. Hypoxia 
 increases sca-1/CD44 co-expression in murine mesenchymal stem cells and enhances 
 their adipogenic differentiation potential. Cell Tissue Res. 341(1): 111-120. 
Weiss, M. L., S. Medicetty, A. R. Bledsoe, R. S. Rachakatla, M. Choi, S. Merchav et al. 2006. 
 Human umbilical cord matrix stem cells: Preliminary characterization and effect of 
 transplantation in a rodent model of parkinson's disease. Stem Cells. 24(3): 781-792. 
Zhang, Y., D. Khan, J. Delling, and E. Tobiasch. 2012. Mechanisms underlying the osteo- and 
 adipo-differentiation of human mesenchymal stem cells. ScientificWorldJournal. 2012: 
 793823.  
Zhou, C., B. Yang, Y. Tian, H. Jiao, W. Zheng, J. Wang et al. 2011. Immunomodulatory effect 
 of human umbilical cord wharton's jelly-derived mesenchymal stem cells on 
 lymphocytes. Cell. Immunol. 272(1): 33-38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
Figure 2.1 Isolation of PUCs from Wharton’s jelly of umbilical cord. 
 
Migration of heterogeneous cells from a Wharton’s jelly explant was observed with 4x 
magnification bright field microscopy after incubation in complete medium for 5 days (A) With 
10x magnification, migrating cells displayed two type of morphology as spindle and round 
shapes (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
Figure 2.2 Adipogenic differentiation potential of PUCs 
 
Adipogenesis-induced PUCs undergo a morphological change from spindle to enlarged spherical 
shape with intracellular lipid droplets (red spots) stained with neutral lipid- specific dye, 
LipidTOX™ Red (A-C). As a negative control, PUCs cultured in growth culture medium 
displayed fibroblast-like morphology without expression of stained lipid droplets (D). Cell nuclei 
counterstained with Syto®16 showed green. Image were taken at 40x magnification with 0.6x 
digital zoom (A-B), 0.8x digital zoom (C) and 0.5x digital zoom (D) on a Zeiss 710 confocal 
microscope 
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Figure 2.3 Flow cytometry analysis for adipogenic differentiation of PUCs. 
 
Histogram illustrates the result of adipogenic differentiation of PUCs after  staining with 
LipidTOX™ Red neutral lipid stain. Gate M1, an open area, is representative of non-induced 
PUCs cultured in complete growth medium. PUCs  undergone the adipogenic differentiation are 
in gate M2, a yellow area. 
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Figure 2.4 Osteogenic differentiation potential of PUCs. 
  
PUCs cultured in osteogenic differentiation medium showed extracellular calcium deposits that 
stained bright orange-red when stained with Alizarin red dye. The image was taken by inverted-
phase contrast microscope (Nikon Diaphot-300) with 4x magnification. 
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Figure 2.5 Chondrogenic differentiation potential of PUCs. 
 
Induction of chondrogenesis in PUCs. Micromass culture was established as described in 
Materials and Methods. Cell pellets stained positively with Alcian Blue indicating the presence 
of proteoglycans a component of the matrix. The image was taken with inverted-phase contrast 
microscope (Nikon Diaphot-300) with 10x magnification.   
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Figure 2.6 Flow cytometric analysis of surface marker expression by PUCs. 
 
Cell suspensions obtained from 4 different cell lines of PUCs were stained with specific mouse 
anti-porcine monoclonal antibodies indicated in filled histograms: CD 90 (A), CD 44 (B), CD 
105 (C), CD 31 (D), CD 45 (E), SLA-DR (F). The empty histogram is the respective IgG isotype 
control. The data shown are representative of those obtained in 4 different experiments. 
 
 
 
86 
 
Figure 2.7 Flow cytometry for DNA content illustrating the synchronization of PUCs 
in G0/G1 phase. 
 
Histogram indicates the distribution of DNA content of PUCs (P3) synchronized into resting 
phase by culturing in the absence of serum. The pink, green and blue filled areas are 
representative of the number of cells within G0/G1, S and G2/M phase respectively.    
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Figure 2.8 The growth curve of PUCs at passage 3 (P3). 
 
The growth kinetics of early passage (P3) PUCs: The average growth kinetics of PUCs was 
measured by determining triplicates cell count number every 12 hours in culture. 
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Table 2.1 Phenotype characterization of PUCs cultured in passage 3. 
Phenotype 
characterization (%) 
PUCs (10
6
 cells) 
1 2 3 4 Mean SE 
CD 90 94.1 93.8 92.6 90.5 92.7 0.82 
CD 44 91.5 90.7 93.1 92.1 91.9 0.51 
CD 105 92.8 90.5 94.2 91.3 92.2 0.82 
CD 31 0.84 0.64 0.72 0.85 0.76 0.05 
CD 45 1.74 1.92 1.54 1.32 1.63 0.13 
SLA-DR 1.32 1.64 1.33 1.24 1.38 0.09 
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Table 2.2 Percentage of viability and G0/G1 phase of PUCs passage 3 (P3) after culturing 
in serum-deprived medium 
PUCs (P3) G0/G1 Phase Viability 
1 92.8 77.5 
2 91.5 76.8 
3 93.4 77.2 
Mean  92.5 77.1 
SE 0.56 0.20 
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Table 2.3 Triplicate collection data of viable PUCs (P3) in 12-108 hours after plating in 
complete growth medium. 
Hours after plating PUCs Cells numbers (x10
4
) 
1 2 3 Mean±SE 
12 1.8 2 1.85 1.9±0.06 
24 2.3 2.3 1.95 2.2±0.12 
36 6.1 5.9 6.2 6.1±0.09 
48 14 15 14.5 14.5±0.29 
60 23 24 24 23.7±0.33 
72 33 32 32.5 32.5±0.29 
84 41 40.5 40 40.5±0.29 
96 42 43.5 43 42.8±0.44 
108 44 44.2 43 43.7±0.37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
 
Chapter 3 - Engraftment Potential of PUCs Transplanted to 
Allogeneic Neonatal Pigs 
 Introduction 
Regenerative medicine is focused on the application of stem-cell technologies to repair, 
replace, or regenerate cells, tissues or organs to restore impaired function that results from any 
cause (Daar and Greenwood, 2007). As this central objective has developed other potentials of 
some stem-cell populations have been identified. Thus the use of stem cells as delivery vehicles 
for various therapeutics has been demonstrated (eg. Rachakatla et al., 2007). Another emerging 
field is the potential trophic, protective, or otherwise beneficial effects of mesenchymal stem 
cells (MSCs) in therapies (Caplan, 2007; Prockop, 2009). MSCs isolated from many adult and 
fetal tissues are a major advance for transplantation therapy. MSCs can be cultured and 
proliferate to high numbers in vitro with the capacity for self-renewal and the potential to 
differentiate into one or more types of specialized cells (Mimeault and Batra, 2008). Evaluation 
of the appropriate route of cell administration is an essential prerequisite for the success of cell 
engraftment for organ repair (Strauer and Kornowski, 2003) and for the other therapeutic 
objectives. High cell concentrations within the areas of inflammation and infarct and minimizing 
homing of transplanted cells into other non-target tissues are desirable. Therefore, regional and 
targeted administration of cells may be preferable unless systemic administration is required. 
Infusion of cells directly into the blood circulation via intravenous routes is the most frequently 
used transplantation method. Arterial and venous thromboses are potential complications and 
may cause morbidity and mortality in recipients transplanted intravenously (Kansu, 2012).  
The intraperitoneal (IP) route is commonly used for therapies such as paracentesis, 
peritoneal dialysis, and chemotherapeutic drug administration (Chua et al., 2009). The advantage 
of IP injection is the large absorbent surface of the peritoneum that allows quick local/systemic 
diffusion (Esquivel, 2009). Stachowska-Pietka et al. (2006) demonstrated that 20–40% of the 
fluid that flows into the tissue from the peritoneal cavity is absorbed by the lymphatics, whereas 
the larger (60–80%) volume of the fluid is absorbed by the blood capillaries. Cells transplanted 
by intraperitoneal injection have been employed mainly prenatally (Flake et al., 1986; Shaaban et 
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al., 1999). The possibility of using the IP route for postnatal systemic cell delivery has been 
suggested (Di Campli et al., 2004; Piscaglia et al., 2005). 
Oral administration is generally not considered for cells because they would be exposed 
to harsh conditions, including digestive enzymes and acidic conditions of the stomach and small 
intestine and if absorbed into the portal system would still be potentially metabolized at the liver 
(Turner et al., 2011). Intestine contains two independent lymphatic networks located in lamina 
propria and muscularis mucosa. Both finally drain the lymph into a common collecting lymph 
vessel found in submucosa layer. Then, the lymph is drained into the thoracic duct prior to 
circulating systematically. It is likely that cells which cross the intestinal epithelium would reach 
the systemic circulation using this route (Miller et al., 2010). Gastrointestinal tracts of neonates 
have pH conditions near neutrality and a low activity of digestive enzymes (Sangild et al., 2000). 
Previously we administered PUCs orally into pre-nursing porcine neonates and detected them the 
in lamina propria of the intestine 8 hours after feeding (Miller et al., 2012). However, allogeneic 
PUCs administered orally were not found in other organs at 8 hours after oral administration.  
The aim of this study was to evaluate the ability of allogeneic PUCs injected peritoneally 
and given orally to healthy neonatal pigs for systemic migration and potential engraftment into 
various tissues. PUCs are porcine umbilical cord matrix stem cells (UMCs) that are generally 
collected perinatally. UMCs have intermediate characteristic between embryonic and adult stem 
cells (Pappa and Anagnou, 2009). Unlike postnatal MSCs, UMCs consistently express 
embryonic stem cell markers and Oct-4, Sox-2, and Nanog are expressed in PUCs (Carlin et al., 
2006). Human UMCs also express markers of pluripotency, such as SSEA-4 and Tra-1-60 (Jo et 
al., 2008). Importantly, these cells also demonstrate characteristics of immunoprivilege, and do 
not form tumor after transplantation. UMCs possessing broader multipotent plasticity and 
proliferate faster than adult MSCs (Weiss et al., 2006; Fong et al., 2011).  
Moreover, because umbilical cords are normally discarded after birth, these stem cells 
could be isolated without ethical concerns (Marcus and Woodbury, 2008). In xenograft models 
using immunocompromised mice, human UMCs transplanted intravenously migrate to tumor 
sites (Rachakatla et al., 2007; Maurya et al., 2010; Ganta et al., 2009) and distribute to various 
tissues of healthy mice after intravenous injection (Maurya et al., 2011). To evaluate the 
potential for allogeneic transplantation we conducted a series of experiments using neonatal pigs 
administered PUCs by oral and IP routes. 
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 Materials and Methods 
 Animal 
Pigs used for these experiments were provided by the Swine Teaching and Research 
Center, Kansas State University. All animal procedures were approved by the Institutional 
Animal Care and Use Committee. 
 Fluorescent dye staining of PUCs and neonatal fibroblasts 
PUCs were labeled with the lipophilic fluorescent dyes PKH26GL (Sigma-Aldrich) or 
CellVue®NIR815 (LI-COR Biosciences, Lincoln, NE). The fibroblasts derived from ears of 
neonatal pigs also were labeled with PKH26GL. The maximum excitation/emission wavelengths 
of PKH26GL and CellVue®NIR815 are 551/567 nm and 786/814 nm. Expanded adherent PUCs 
were harvested from tissue culture flasks using trypsin/EDTA and as a single cell suspensions. 
Approximately, 1x10
7
 cells were washed with serum free medium, and centrifuged (400 x g). 
The supernatant was aspirated and the cells were resuspended and dispersed with 1 ml of Diluent 
C provided by the manufacturer. Immediately prior to staining, 4x10
-6
 M of either PKH26GL or 
CellVue®NIR815 dye solution was prepared by adding 4 µl of 1x10
-3
 M dye stock in ethanol 
into 1 ml of Diluent C in a polypropylene centrifuge tube and mixing to disperse. The 1 ml of 
cell suspension was added rapidly to 1 ml of dye solution and incubated 25°C for 5 minutes. The 
staining reaction was stopped by adding an equal volume of serum and incubated for 1 minute. 
The serum-stopped sample was diluted with an equal volume of complete medium. The stained 
cells were centrifuge (400 x g) for 10 minutes 25°C and the supernatant removed. The stained 
cells were washed twice with serum free medium to eliminate excess dye and resuspended in 
high-glucose Dulbecco’s Minimum Essential Medium with HEPES (GlutaMAX™-DMEM-
HEPES, Invitrogen) at a concentration of 1x10
7
cells/ml.  
To verify cell staining and viability, PKH26GL stained cells were stained with 0.05 µM 
of cell-impermeant cyanine dye, SYTOX® Green dye (Invitrogen), with excitation and emission 
maxima of 504 nm and 523 nm. Double fluorescent dye stained-PUCs were detected by the 
emitted red and green fluorescence in PM3 and PM2 channels of a microcapillary cytometer 
(Guava EasyCyte Plus, Millipore). PUCs stained with CellVue®NIR815 were verified by plating 
2x10
5
 cells (approximately) in a well of a 96 black-well plate before using IVIS Lumina II 
imaging system (Caliper Life Sciences) with 745 nm excitation laser line and BP 810-875 nm 
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filter for detection of fluorescence emission. Viability of CellVue®NIR815-stained cells was 
evaluated by the dye exclusion method using 0.4% trypan blue dye (Gibco®). 
 Cell administration to pigs 
The fluorescence-dye labeled PUCs were administrated to pre-nursed and nursed 
newborn pigs by oral feeding. They also were injected intraperitoneally into neonatal, 1-day, 1 
week, 2-week and 3-week old pigs. Fibroblasts stained with PKH26 were injected 
intraperitoneally into post-colostral newborn pigs. Pigs were weighed and ear tagged before 
administration of labeled PUCs. Subsequently pigs were ear notched to provide two means of 
identification. For oral feeding, sows were observed during farrowing and newborn pigs were not 
allowed to nurse until cells were fed (<1 h following birth). Oral feeding of nursed pigs was also 
evaluated in newborn pigs allowed to nurse and about 1 hour after birth. Feeding of the labeled 
cells was by a modified 12 French feeding tube (Kendall Healthcare, Marietta, Georgia), cut to 
187 mm in length. The feeding tube was placed behind the tongue and labeled PUCs suspended 
in 3 ml of complete medium were administered with a 5 ml syringe. The pig was observed to 
swallow the labeled cell suspension during feeding and the feeding tube was flushed with PBS (1 
ml) to wash any the residual cells through the tube. The treated pigs were returned to the 
farrowing crate for ad libitum nursing until sacrifice. For IP injections, pigs were restrained by 
holding the rear legs with the head down before injection. The labeled PUCs were injected in 3 
ml of serum free medium into the peritoneal cavity using an 18 gauge 1-1/2” needle placed on 
the right side lateral to the teat line and between the first and the second pairs of nipples. The 
pigs were returned to the sow and observed for 30 minutes. 
 Pig Sacrifice 
Pigs were sacrificed by first anesthetizing by inhalation of Isoflurane (1-5% in O2) 
administered to effect via a cone placed over the nose. Once pigs reached to a deep surgical 
plane with no palpebral or pedal reflex, they were sacrificed by intracardiac injection of a 
saturated solution of potassium chloride to induce cardiac arrest. 
 Blood and tissues collection 
Blood samples (10 ml) from each treated and control pig were collected directly from the 
heart prior to KCl injection and transferred into evacuated blood collection tubes containing 
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sodium heparin. Blood was refrigerated until processing. Following sacrifice, the pig was 
positioned dorsally and the trunk opened longitudinally. Tissues were collected from the heart, 
lung, pancreas, liver, kidney, omentum, stomach, intestine, uterine horn, ovary, muscle and bone 
marrow. The whole intestine was opened longitudinally and intestinal lumen washed with tap 
water. The duodenum, jejunum, ileum, cecum and colon were separated and kept in ice cold 1X 
HBSS containing Ca
2+
 and Mg
2+
. All parts of intestines were scanned to locate fluorescent 
positive area using IVIS Lumina II imaging system (Caliper Life Sciences). All pieces of 
collected organs including fluorescent positive and negative areas of all parts of intestines were 
collected and preserved in DMSO/EDTA/Saturated NaCl buffer (DESS) buffer and 4% 
paraformaldehyde solution (16%, Thermo Scientific) for cryosection and DNA isolation. 
  Cell isolation from blood and bone marrow 
Femurs of sacrificed pigs were removed, cleaned of all connective tissues and placed in 
ice-cold PBS containing antimycotic/antibiotic reagent (Gibco, 1:100). The ends of femurs were 
cut to expose the marrow. To prevent clotting, the marrow was flushed from both ends with 
DMEM containing 5 mM EDTA using a 3 ml syringe with an 18-g needle. Isolated cells were 
centrifuged (400 x g) for 8 minutes and suspended in 5 ml of red blood cell lysis buffer (Sigma) 
for 5 minutes. Cells were again pelleted by centrifugation (400 x g) for 8 minutes and washed 2 
times with PBS. Bone marrow cells were suspended in PBS and evaluated by flow cytometry or 
were cultured with complete growth medium in tissue culture flasks (25 cm
2
) until they reached 
85-90% confluence. Cultured cells were harvested and their chromosomal DNA was isolated to 
determine the presence of the Y-chromosome gene, SRY gene, by PCR. Blood of female 
recipients was diluted 1:1 with PBS before centrifugation (400 x g) for 8 minutes. The cell pellet 
was suspended in 10 ml of red blood cell lysis buffer for 10 minutes followed by washing 2 
times with PBS. The isolated blood cells were suspended in 200 µl of PBS before they were 
evaluated by flow cytometry or PCR. Chromosomal DNA of cells derived from female recipient 
blood was isolated and used as a template to detect SRY gene of engrafted male donor cells by 
PCR. Cells isolated from blood and bone marrow of female recipients were suspended with 200 
µl of PBS. Expression of transplanted PKH26- labeled male PUCs in cell suspensions were 
detected by a microcapillary cytometer (Guava EasyCyte Plus, Millipore) using the red filter 
channel, PM3. 
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 DNA isolation 
Collected tissues (25 mg) preserved in DMSO/EDTA/sodium chloride solution (DESS) 
were placed in a dish with water for a few minutes to remove any salt or DESS that might be 
attached. The washed tissue was transferred to a microcentrifuge tube and homogenized using a 
pellet pestle (Sigma). Total DNA was isolated from homogenized tissues using DNeasy Kits 
(Qiagen) according to the manufacturer’s instructions. Briefly, the disrupted tissue was lysed by 
tissue lysis buffer and proteinase K. Tissue lysates were treated with RNase and cell lysis buffer. 
Cell lysates were mixed with molecular-grade ethanol and transferred into DNeasy spin columns. 
Total genomic DNA was eluted from spin columns and quantified using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
 Polymerase chain reaction (PCR) 
Two micrograms of total genomic DNA was used as the template for 50 µl PCR 
reactions. The PCR reaction was carried out using the HotStar Taq DNA Polymerase Kit 
(Qiagen) which included 10X PCR buffer (15 mM Mg
2+
 plus), 25 mM MgCl2, 5X Q solution 
and 5 U/µl HotStar Taq DNA polymerase. Each PCR reaction contained 1X PCR buffer, 2.0 mM 
MgCl2, 0.8mM dNTP (Advantage Ultrapure Nucleotide, Clonetech), 1X Q solution, 0.05 U/µl of 
HotStar Taq DNA polymerase, and 0.28 µM specific porcine SRY forward and reverse primers 
(Forward: 5’-GGCTTTCTGTTCCTGAGCAC-3’, Reverse: 5’-
CTGGGATGCAAGTGGAAAAT-3’, product size: 247 bp) and porcine-specific beta-actin 
genes forward and reverse primer (Forward: 5’-GTCATCACCATCGGCAATGA-3’, Reverse: 
5’-CGTGAATGCCGCAGGATT-3’, product size: 183 bp). PCR conditions were 1 cycle of 15 
min at 95 °C, followed by 35 cycles of 30 sec at 95°C, 30 sec at 59°C, and 30 sec at 72°C, and 
finishing with 7 min incubation at 72°C.  PCR reaction products stained with ethidium bromide 
were visualized by agarose gel electrophoresis. 
 Agarose gel electrophoresis 
The agarose gel (2.5%) was prepared in 1X TBE and ethidium bromide (250 ng/µl). 
Loading dye (6x; 5µl) was added to the PCR reactions (25 µl) and mixed prior to loading into 
wells of agarose gel. Agarose gels were run at 100 volts for approximately 1 hour. A DNA 
ladder (100 bp) was included and the DNA was visualized under UV on a transilluminator and 
photographed with a Polaroid camera. 
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 Digoxigenin (DIG) labeled DNA probes synthesis 
Based on PCR reaction, 377 bp of dsDNA probes specific to porcine Y chromosome, 
SRY, was synthesized and labeled with digoxigenin (DIG) using a PCR DIG Probe Synthesis Kit 
(Roche). The kit was comprised of PCR buffer with 15 mM MgCl2 (10X), PCR DIG Probe 
synthesis Mix (10X) and enzyme mix. Synthesis of DIG-labeled DNA probes followed the 
manufacturer’s instructions. Briefly, 50 ng of male genomic DNA isolated from male PUCs was 
added to 50 µl PCR reaction contained with 1X PCR buffer with 1.5 mM MgCl2, 1X PCR DIG 
Probe Synthesis Mix containing dNTPs and DIG-11-dUTP, 0.75 µl of enzyme mix and 0.25 µM 
of specific porcine SRY forward and reverse primers (Forward: 5’-
AATCCACCATACCTCATGGACC-3’, Reverse: 5’-TTTCTCCTGTATCCTCCTGC-3’, 
product size: 377 bp). PCR conditions were 1 cycle of 2 min at 95 °C, followed by 35 cycles of 
15 sec at 95°C, 60 sec at 60°C, and 15 sec at 72°C, and finishing with 7 min incubation at 72°C.  
Digoxigenin (DIG) labeled DNA probes were isolated and purified from PCR reactions using 
QIAquick PCR Purification Kit (Qiagen) according to the manufacturer’ instructions. PCR 
reactions were treated with high chaotropic salts buffer and ethanol to facilitate precipitated 
DNA probe to bind to a silica membrane of QIAquick PCR Purification spin columns before the 
purified DNA probes were eluted with elution buffer. Size and purity of eluted DIG-labeled 
dsDNA probes were determined by staining with ethidium bromide and visualized by agarose 
gel electrophoresis. The DIG-labeled dsDNA probes were approximately quantified according to 
the density of ethidium bromide-stained 100 bp DNA ladder. 
 Re-culture of intestinal transplanted PUCs 
Pieces of the exposed and cleaned intestines (15-20 cm) were collected in ice-cold serum 
free culture medium until processing for cell isolation. The collected pieces of inverted intestines 
were incubated in 1 mM EDTA mixed with 1mM dithiothreitol (DTT) in PBS without Ca
2+
 and 
Mg
2+
 for 7 minutes at 37°C to remove mucus and intestinal epithelial cells. The pieces of 
intestines were washed 5 minutes twice in PBS without Ca
2+
 and Mg
2+
 at room temperature, 
then, placed incubated in enzymatic digestion solution (100 ml) with shaking (low speed) at 
37°C for 45 minutes. The enzymatic solution was comprised of collagenase type 3 (220 u/ml), 
neutral protease (0.5 u/ml) and deoxyribonuclease type 1 (50 u/ml) (all enzymes were from 
Worthington) in complete growth medium. The pieces of intestine were removed and the 
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enzymatic reaction inactivated by incubating at 4°C for 5 minutes. The isolated cell suspension 
was filtered (Steriflip® 60 µm pore size; EMD Millipore), then centrifuged (500 x g for 10 
minutes at 4°C). The cell pellet was washed twice with PBS (room temperature). Recovered cells 
were plated on chamber slides (Lab-Tek® II Slide) and a tissue culture flask (75 cm
2
) for 
detection of transplanted PUCs engrafted in intestines using FISH and PCR methods. 
 Slide preparation for fluorescent in situ hybridization (FISH) 
Intestinal cells isolated from small intestines using the enzymatic digestion procedure 
were cultured in complete growth medium at 38.5°C for 7-10 days with the medium replaced 
every 3 days. After culture the medium was removed and the slides were washed 3 times with 
PBS, fixed with cold methanol: glacial acetic acid (3:1) for 10 minutes. The cells were washed in 
PBS for 5 minutes, 3 times before the fixed cells were incubated in 10 mM sodium citrate (pH 
6.0) at 96 °C for 15 minutes. Slides were air-dried at room temperature (5 minutes) and washed 2 
times (5 minutes each) in 2X SSC solution at room temperature. Subsequently, the slides were 
treated with 200 µl of 100 µg/ml of RNase A (Sigma) in 2X SSC for 1 hour at 37 °C and washed 
2 times, 5 minutes in 2X SSC solution at room temperature. Then, the slides were rinsed with 10 
mM HCl for 2 minutes and treated with 200 µl of 40 U/ml of pepsin (Sigma) in 10 mM HCl for 
10 minutes at 37 °C. The enzyme-treated slides were rinsed with distilled water and washed 2 
times for 5 minutes in 2X SSC solution at room temperature. The slides were dehydrated by 
passing through a series of ethanol concentrations (70%; 85%; 100%) and air-dried. 
Chromosome denaturation was carried out in 70% (v/v) formamide/2X SSC solution at 75 °C for 
5 minutes. The slides were dehydrated by passing through a series of ethanol concentrations 
(70%; 85%; 100%) and air-dried. 
 Fluorescent in situ hybridization and detection 
HybriwellTM (Sigma), a slide sealing system, was installed over the slide. One hundred 
and fifty microliters of a hybridization mixture containing 24 µl of purified DIG-labeled DNA 
probe solution derived from 2 PCR reactions and 126 µl of hybridization buffer was prepared. 
The HybriwellTM was filled with hybridization mixture before it was sealed with adhesive 
plastic. The slide was incubated (75°C for 5 minutes) to denature DIG-labeled DNA probes and 
then incubated in a dark moist chamber at 37°C (24 hours) for probe hybridization. The post-
hybridization steps started when the HybriwellTM was removed from the slide and excessive 
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DIG-labeled DNA probes were washed out by incubating the slide two times for 5 minutes in 2X 
SSC buffer at room temperature. Then the slide was placed in 50% formamide/2X SSC solution 
for 2 minutes at 42°C. Subsequently, the slide was passed through in 3 wash steps, 2 times in 2X 
SSC buffer for 15 minutes at 42°C, 2 times in 1X SCC buffer for 15 minutes at 42°C and two 
times in 0.5X SSC buffer for 10 minutes at room temperature.  
After the post-hybridization washing steps the slide was washed 3 times in PBS for 5 
minutes at room temperature and then blocked for non-specific binding by incubating in 1% 
normal goat serum and 0.1% Triton X-100 in PBS for 30 minutes at room temperature. The 
blocking solution was poured off and the slide was incubated with 200 µl of conjugation buffer 
containing 1:15 of conjugate stock solution and blocking solution for 12 hours at 4°C. The slide 
was washed three times in PBS for 5 minutes at room temperature and rinsed two times with 
distill water. Cell nuclei were counterstained with 200 µl of 0.05 µM green-fluorescent nucleic 
stain, Syto®16 (Invitrogen) contained maximum excitation/emission as 448/518 for 8 minutes at 
room temperature. The slide was mounted with glycerol and fluorescence evaluated using 
confocal microscopy.  Detection of DIG-labeled DNA hybridized probes was performed by 
direct fluorescence detection. Fab fragments from an anti-digoxigenin (DIG) antibody 
conjugated with 5-carboxy-tetramethyl-rhodamine-N-hydroxy-succinimide ester (TAMRA) 
(Roche) with maximum excitation/emission as 555/580 bound directly and specifically to DIG-
labeled DNA probes. 
 Confocal microscopy 
Slides were examined using an inverted Zeiss LSM 700 confocal microscope (LSM 700, 
Carl Zeiss). The 20x/0.50 and 40x/1.30 Oil M27 EC Plan-Neofluar objectives with a pinhole 
opened 33 µm were used to visualize cells within a field of view of 266.5 x 266.5 and 319.8 x 
319.8 μm, respectively. Image size and dynamic range were 1024 x 1024 and 8 bit. Scanning 
speed number, mode of scanning and averaging number of signal/noise ratio were 6, line mode 
and 4, respectively. Sequential excitation at 2% of 488 nm and 2% of 555 was provided by argon 
and helium-neon gas lasers. To scan of cells labeled with TAMRA and Syto®16, emission filters 
BP 500-530 and LP 580 were used for collecting green and red in channels one and two with the 
master gain of each channel at 400-450 and 670-715 respectively Emission filters BP 490-535 
and LP 568 were used for collecting green and red in channels one and two with the master gain 
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of each channel as 400-450 and 670-715 respectively to scan cells labeled with PKH26 and 
Syto®16. After sequential excitation, green and red fluorescent images of the same cell were 
saved and analyzed by Zeiss Zen 2010 software. 
 Cryosection 
The 4% paraformaldehyde fixed tissues obtained from sacrificed pigs were washed 3 
times (10 minutes each) with PBS and subsequently incubated in 30% sucrose (w/v) in PBS for 
24 hours at 4°C. Tissues were treated with cryoprotectant and submerged in cryomolds (Tissue-
Tek®) containing embedding medium (Tissue-Tek®) and frozen in liquid nitrogen for 5 
minutes. The frozen tissues were stored at –70°C until cryosectioning. The frozen tissues were 
kept in the cryostat chamber at -20°C for 1 hour prior to cryosectioning. The tissue specimen 
block was removed from the cryomold, placed on the chilled cryostage and sectioned at 12 µm 
thickness with a cold razor blade and anti-roll plate. Then, each tissue section was gently 
transferred and melted on Probe On™ Plus Microscope Slides (Fisher Scientific). The section 
was allowed to adhere to the slide at room temperature for at least 2 h and kept at -20°C until 
processing to visualize with the confocal microscope. 
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 Results 
 Labeling PUCs with fluorescent dye 
After staining with PKH26, early passage of PUCs and neonatal fibroblasts (P2-P3) 
emitted bright red fluorescence (Fig 3.1A) and were nearly all (98%) stained (Fig 3.1B) 78.6% of 
PKH26 labeled PUCs were viable (3.2B) comparable to 78.8% viability of unstained PUCs (Fig 
3.2A). PKH26 labeled fibroblast viability was 85% viability after evaluating by the trypan blue 
exclusion method. PUCs were also stained with lipophilic near infrared fluorescent dye, 
CellVue® NIR 815 with the same method as for PKH26 staining and they illustrated high 
emitted fluorescence (Fig 3.3). Viability of CellVue® NIR 815-labeled cells was evaluated by 
the trypan blue exclusion method that indicated 80-85% viability of stained cells. 
 Transplantation of fluorescent stained PUCs orally and by intraperitoneal injection 
Initially, the PUCs were transplanted in medium with serum (20% FBS) and 2 recipients 
(2 weeks old female pigs) of 16 recipients transplanted intraperitoneally showed symptoms of 
anaphylaxis with  labored breathing, vomiting and pale skin within 5-10 minutes. Both appeared 
to recover within one hour but one died within 24 hours and the other recoverd with no further 
symptoms. Subsequent IP transplantations in 3 recipients were in medium without serum and 
these symptoms were not observed. There were also no indications of reactions when the PUCs 
were given orally into 6 recipients with serum in the transplant medium.                                                                                                                                                                                                                                                                                                                                                                                                                               
 Tissues collection and intestine screening 
The processed fresh whole intestine was approximately 350-430 cm long and was 
scanned under red and near infrared filters of the IVIS imaging system to indicate the areas of 
potential PKH26 and NIR815-labeled donor cells engraftment. Emitted red fluorescing areas 
were found for small and large intestines of female recipients transplanted by PKH26-labeled 
donor cells after scanning. However, there were fluorescent areas also in intestines of 
untransplanted control female pigs. The presence of autofluorescence complicates the use of 
IVIS scanning to detect areas of engrafted cells. Positive and negative fluorescent areas of 
intestines of recipients were collected to detect engrafted male PUCs and neonatal fibroblasts. 
Scanning the fresh whole intestine of female transplanted with NIR815-labeled male PUCs and 
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untreated control female pigs showed no fluorescing areas. Because the labeled cells were not 
found with these scans random collection of small and large intestine tissues was performed. 
 Detection of transplanted male PUCs in female recipients 
Nursed-newborn female piglets transplanted with donor cells by intraperitoneal route 
were sacrificed post transplantation for 6 hours (n=2) and 24 hours (n=2) and tissues (n=3 per 
tissue) collected. DNA isolated from all tissues except blood and bone marrow was analyzed for 
expression of the male gene, SRY. PCR analysis indicated that allogeneic male PUCs were 
present in all tissues. At the earliest sacrifice (6 h), transplanted male PUCs were found in the 
omentum and diaphragm in relatively large amounts (Fig 3.4A) and 24 h (Fig 3.4B) post-
injection. The lowest detection of PUCs was in the mesenteric lymph nodes (Table A.1). Cells 
isolated from blood were negative for emitted red fluorescent detection analyzed by flow 
cytometry. Blood cells were not checked for expression of the SRY gene by PCR. 
Using PCR to detect the SRY gene, male PUCs transplanted orally into pre-nursed pigs 
were found broadly in the gastrointestinal tract, liver, spleen, mesenteric lymph nodes, pancreas 
and omentum at 1 week post-administration. A lower incidence of PUCs was seen in heart, lung, 
kidney and bone marrow (Fig 3.5A). There was no SRY gene expression for cells in the blood 
(Table A.2). Tissues were not collected from nursed female recipients fed PKH26 labeled male 
PUCs for PCR-based SRY detection. Blood collected from these recipients was absent of red-
fluorescent donor cells as indicated by flow cytometry analysis. 
When intraperitoneal injection was used to administer PUCs, all tissues, including cells 
from bone marrow (but not the blood) were positive for the SRY gene in female recipients of all 
ages (Fig 3.5-3.8). Incidence of detected PUCs was low for the mesenteric lymph nodes of all 
ages. Two- and three-week old female recipients showed the presence of allogeneic male PUCs 
one week post transplantation in tissues derived from uterine horns, urinary bladder, and muscle 
(semimembranosus). There was no positive signal for the SRY gene from cells isolated from 
blood at sacrifice for any recipients of any age (Table A.2).  
Cryosection of intestines and organs collected from newborn pig recipients transplanted 
with PKH26-labeled PUCs and fibroblasts were visualized with confocal microscopy. Dispersion 
of red fluorescent labeled cells was found in intestinal mucosal layer of pre-colostral and post-
colostral newborn pigs administered orally and intraperitoneally respectively. PUCs were mostly 
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detected in the base of villi and the areas around the intestinal crypts of small (Fig 3.9B, 3.9C 
and 3.9D) and large intestines (Fig 3.10B and 3.10D). Also, they were detected in cryosections 
of spleen (Fig 3.11B), kidney (Fig 3.11D) and stomach (Fig 3.12B). Compared to PUCs 
engrafted in the recipient intestines, PKH26 labeled-fibroblasts given by IP injection were found 
similar sites (Fig 3.10A). There were no cells containing red fluorescent spots in cryosections 
obtained from non-transplanted recipients (Fig 3.9A, 3.10C, 3.11A, 3.11C and 3.12A). Tissue 
cryosections derived from nursed newborn pigs fed with PKH26 labeled PUCs did not have red-
fluorescent donor cells.   
Intestinal cells from all transplantation ages of orally and intraperitoneally transplanted 
recipients were isolated by enzymatic digestion and cultured in vitro. After plating, attachment of 
isolated intestinal cells was observed in two days and colonies formed within ten days. 
Fluorescent in situ hybridization (FISH) analysis with DNA probes specific to SRY gene  
performed after two weeks culture revealed transplanted male PUCs derived from the intestines 
of recipients  orally and intraperitoneally transplanted PUCs (Table A.3 and Fig 3.13A). 
Colonies of donor male PUCs also were detected by FISH when intestinal cells were plated at 
low cell density (Figure 3.13B). PCR confirmed the presence of the SRY gene in these cultured 
intestinal cells (Figure 3.14). 
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 Discussion 
The ability of transplanted cells to engraft and survive in the host is an important 
consideration for the application of stem-cell therapy. Migration and engraftment of MSCs after 
local and systemic transplantation has been the subject of several reports. Allogeneic 
transplantations have also been studied for adult MSCs such as BM-MSCs and adipose tissue 
derived MSCs. These cells are reported to migrate to and engraft into sites of infact and injured 
areas after intravenous and intraperitoneal administration (Wang et al., 2011; Castelo-Branco et 
al., 2012; Wise et al., 2012). There also have been reports that BM-MSCs distribute into various 
organs after systemic delivery with low frequencies (Devine et al., 2003). 
Xenogeneic and allogeneic fetal MSCs derived from placenta and amniotic fluid showed 
engraftment in various normal tissues of fetal and neonatal rats after in utero and IP 
transplantation (Chen et al., 2009). IP injection of human fetal MSCs into osteogenesis imperfect 
neonatal mice resulted in engraftment in the injured tissues (Jones et al., 2012). 
Wharton’s jelly-derived MSCs are potentially useful for various medical therapies. They 
are simple to harvest, abundant, mutipotent, highly proliferative and have low immunogenicity 
(Cho et al., 2008). Specifically relevant to the work reported here, migration and engraftment of 
human umbilical cord matrix stem cells (hUCMS) in immune deficient mice after intravenous 
injection has been studied. The cells were found non-randomly engrafted in various normal 
tissues (Maurya et al., 2011).  
We reported that allogeneic PUCs were capable of trans-epithelial trafficking and 
incorporation into deep layers of intestine of pre-colostral neonatal pigs when given orally 
(Miller et al., 2012). The present report expands on this observation and extends it by including 
intraperiotoneal administration. Moreover, the isolation and re-culture of transplantated PUCs 
from the intestinal mucosa indicates the cells are viable and mitotically competent after 7 days. 
PUCs migrated from both the intestinal lumen and the peritoneal cavity, and engrafted in 
multiple tissues and persisted for at least 7d, the longest time studied in the current investigation.  
Their recovery from the stromal layer of the intestine and re-culture with the formation of 
colonies indicates that at least in these characteristics they have retained their mesenchymal 
phenotype. Further work will be required to fully characterize the recovered cells.  In addition to 
the potential of MSCs to differentiate and contribute to tissue regeneration, they are also reported 
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to contribute supportive and protective effects. In this regard maintenance of mesenchymal 
phenotype and residence in the stromal compartment of tissues is an important ability. 
Using sex mismatched donor cells with PCR and FISH to detect the Y-chromosome gene,   
SRY, was a key method for this work. As reported in our earlier work the oral feeding of 
allogeneic PUCs into non-nursed newborn pigs is a safe and effective procedure. Oral delivery of 
allogeneic donor cells resulted in migration and engraftment into a variety of distant organs. 
However, the requirement for administering the cells before the pig nurses is inconvenient and 
limits the recipient age that can be studied. It is expected that the harsh condition of gut that is 
established after nursing would be lethal for the PUCs and our preliminary studies confirmed that 
no transplanted cells were detected when they were fed after the recipient had nursed (Miller et 
al., 2012). The formed milk curds that form in the stomach after nursing probably trap the orally 
administered cells and and create an inhospitable environment for survival and trans-epithelial 
trafficking. 
Before nursing the physiological conditions of gastrointestinal tracts of newborn pigs are 
close to neutral pH with low digestive enzyme activity. Moreover, culture medium administered 
orally with PUCs contains high buffer capacity that may prevents rapid change in pH. It is likely 
that oral-fed PUCsat a size of 8-20 µm (Majore et al., 2009) are able to penetrate through 
incompletely formed intercellular junctions of the intestinal epithelium of pre-colostral neonatal 
pigs and this may be the same mechanism used by colostral lymphoid cells as they are absorbed 
from digestive track into immune system of newborn pigs (Tuboly et al., 1988).  
The gastrointestinal tract and internal organs of the abdominal compartment were the 
major sites for transplanted PUC with 75-100% of these organs containing PUCs 1 week after 
oral administration. PUCs were detected in the heart, lung, kidney and bone marrow but less 
frequently (37.5-50%). 
Likely, allogeneic PUCs migrate from mucosa layer of intestines to mesenteric lymph 
nodes via the lymphatic system similar to the migration pattern of colostral leukocytes 
(Williams, 1993). However, they do not appear to reach the general circulation in large numbers 
or according to the pattern reported for colostral leukocytes.  The portal venous system drains the 
venous blood from the visceral organs of the stomach, intestines, spleen, pancreas, omentum to 
liver by veins. Zhou et al (2000) reported the accumulated maternal leukocytes were found at a 
perisinusoidal capillary region of the neonatal liver of mice after foster nursing on a GFP 
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transgenic mother (Zhou et al., 2000). It is probable that incompletely developed venous valves 
of newborn pigs allow migration of male PUCs from intestines to reach multiple tissues linked 
by the portal system. Then, the donor cells possibly moved from portal system by the hepatic 
vein into inferior vena cava and engrafted in heart, lung and bone marrow. 
IP injection is a convenient and simple method for administer PUCs to neonatal pigs. The 
peritoneal cavity is a space surrounding the viscera in the abdomen. Its large surface with 
abundant vascularization provides a portal of entry to the general circulation. Water, solutes and 
cells can be transported across the mesothelium lining of peritoneal cavity to the blood stream 
via the lymphatic system (Flessner, 1991). Fluid, macromolecules and cells from the peritoneal 
cavity are drained into the diaphragmatic lymph system through mesothelial stomata prior to 
passing through mesenteric, retroperitoneal channels and associated lymph nodes. Then, the 
lymph is passed into the thoracic duct before entering the blood circulation (Abu-Hijleh et al., 
1995). Mesothelial stoma overlying milky spots in the omentum is also an entrance route for 
cells migrating from peritoneal cavity into lymphatic system (Mironov et al., 1979).  
Neonatal fibroblasts were also detected in intestinal mucosa layer of newborn pigs after 
IP injection. Fibroblasts have phenotypic and functional resemblance with MSCs and global 
gene and micro RNA expression profiles of MSCs and fibroblasts have shown them to be similar 
(Bae et al., 2009). This could be consistent with the finding MSCs and fibroblast in the same 
regions after transplantation. However, the two cell types differ markedly in that genes 
functioning in cell plasticity are highly expressed in MSCs compared to fibroblasts (Bae et al., 
2009). The study of Pereira et al (2011) in rat model of Parkinson’s disease (PD) demonstrated 
that fibroblast engraftment was not promising treatment as cell-based therapy due to their 
absence of immunomodulatory properties. Fibroblasts have also been observed to cause scar 
formation after transplantation which further limits their usefulness.   
There are concerns about intravenous cell transplantation resulting in cell emboli that 
block blood vessels and causing death when large numbers of cells are transplanted, at least in 
mice (Plock et al., 2013). Moreover, cells administered by intravenous injection could be trapped 
in the lung capillaries in a phenomenon known as “transpulmonary first-pass attenuation” 
(Strauer and Kornowski., 2003). Intraperitoneal delivery of human umbilical cord blood cells in 
a rodent model showed migration and engraftment in different organs such as bone marrow, liver 
and spleen. These transplanted cells could reduce liver damage in an immunocompetent rat 
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model of toxic liver injury. The homing ability of stem cells to injured organ after intraperitoneal 
injection was directly related to severity of the organ damage (Piscaglia et al., 2005). 
In the current study, the earliest observation were at 6 hours after IP injection with the 
PUCs detected in the diaphragm and omentum in all samples examined at 6 and 24 hours after 
injection. In contrast, lower frequency of PUCs (<50%) was found in other tissues at 6 hours 
compared to detection in most tissues at 24 hours. It appears that the omentum and diaphragm 
are the major sites of entrance for the donor cells.  
It is somewhat surprising that the IP-administered PUCs were detected at a high 
incidence in all the regions of the small intestine. Confocal imaging showed that they were 
located around base of villi and intestinal crypts. There have been reports illustrating that BM-
MSCs transplanted systemically into irradiated animals could migrate to engraft in the lamina 
propria and pericryptal intestinal mucosal layer (Brittan et al., 2002; Zhang et al., 2008) and 
PUCs given IP showed a similar ability. The intestinal mucosal layer is a loose connective tissue 
with abundant capillary networks and lymphatic vessel including lacteals. The intestinal 
lymphatic system found in the mucosa layer is the initial lymphatic network comprising of blind-
end vessels without smooth muscle and valves. Initial lymphatic vessels are formed by a single 
layer of endothelial cells that attach to intestinal connective tissues and drain the lymph 
following the force generated by intestinal peristalsis (Miller et al., 2010). Overlapping flaps at 
the borders of oak leaf-shaped endothelial cells of the initial lymphatic vessels open during 
vessel expansion due to extrinsic force. The openings allow the entrance of lymph from 
interstitial space and leukocytes (Baluk et al., 2007). Possibly, PUCs in the intestinal mucosa use 
the intestinal lymphatic network for migration through the entire intestines.  
Weiss et al. (2003) reported that PKH26 labeled UMCs administered intravenously 
migrated and engrafted in the parenchyma of the recipients kidney. The present study also found 
the labeled PUCs in spleen, stomach and kidney after IP injection. It is possible that PUCs 
injected intraperitoneally were able to migrate and engraft to organs through the recipient blood 
circulation. 
Blood collected from female recipients one week after oral and IP injection was negative 
for expression of SRY using PCR. Because PCR is highly sensitive, these results suggested that 
donor PUCs were not in the circulation at that time, although they may have been earlier. Flow 
cytometry analyses for PKH26 labeled PUCs in blood collected at 6 hours and 1 day after IP 
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administration also were negative however PCR was not used for these samples. Therefore a low 
concentration of donor PUCs, if it occurred, could have gone undetected. Therefore the route of 
migration of PUCs is unresolved. 
A novel aspect of the current work is the recovery of transplanted PUCs from the mucosa 
of recipients. Cultured intestinal cells were positive for SRY gene after analysis by PCR and 
FISH identifying donor male PUCs in the cultured cells. The donor male PUCs attached to 
culture flasks and had fibroblast-like morphology. Moreover, these re-cultured male PUCs were 
proliferating as they formed colonies. Therefore engrafted male PUCs were able to survive and 
express self-renewal after recovery from the host small intestines after oral and intraperitoneal 
transplantation. 
Earlier we found that PKH26-labeled PUCs were found in the bright spot detected by 
IVIS Lumina II imaging. Here we found that freshly washed intestine obtained from non-
transplanted control as well as recipient pigs transplanted with PKH26-labeled donor male PUCs 
showed fluorescent positive areas. Positive and negative fluorescent areas of recipient intestines 
transplanted with PKH26-labeled donor PUCs were checked for expression of SRY by PCR and 
the frequency of positive signal was similar. Residual intestinal contents emitted at the same 
wavelength as PKH26 dye and were probably the cause of false fluorescent positive areas. To 
avoid auto-fluorescent background, the near infrared dye (NIR 815), which has been used for 
noninvasive real-time cell tracking in small animal models (Armentero et al., 2013) was used to 
label donor PUCs before intraperitoneal transplantation. There were no fluorescent positive areas 
detected on both non-transplanted control and recipient intestines transplanted with NIR 815-
labeled donor PUCs following screening with IVIS Lumina II imaging system set at the 
line/filter wavelength of 745/BP810-875 nm, however, randomly collected fluorescent negative 
areas of intestines showed positive for SRY gene after using PCR for detection. The NIR 815 
labeled donor PUCs in the recipient intestines probably emitted too low a fluorescent signal to be 
detected. 
In conclusion, allogeneic donor PUCs administered orally into pre-nursed piglets and 
intraperitoneally into neonatal to weaning pigs were found in the intestines and several other  
organs both in intra-peritoneal (i.e. gut, liver, spleen) and extra-peritoneal (i.e. kidneys, bladder, 
uterus) organs. Also, they were able to incorporate in muscle and thoracic organs including heart 
and lung. Distribution of PUCs to various organs could be related to the proximity of the 
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abdominal organs to delivery site and cell migration toward the tissues might occur both via 
lymphatic drainage and the blood, but also directly through the serosa. The presence of PUCs in 
organs was observed 6 hours after IP injection and the donor PUCs were able to persist in the 
organs at least 1 week. Donor PUCs implanted in small intestines for 1 week were viable and 
exhibited self-renewal after re-culturing in vitro. In light of these results, the IP and oral 
administration of stem cells are potential routes for cell therapy in pediatric disorders. 
In the future, the persistence and differentiation of PUCs could be explored perhaps by 
using genetically modified PUCs expressing exogenous near infrared fluorescent or 
bioluminescent genes. Moreover, migration and engraftment of either genetically modified PUCs 
to up-regulate homing receptor or normal PUCs transplanted via intraperitoneal injection to local 
and systemic tissue damage as in irradiated animals, intestinal ischemic model or intestinal 
inflammation model would be intriguing studies. 
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Figure 3.1 Labeling of PUCs with lipophilic fluorescent dye. 
 
 Early passage of PUCs labeled with the lipophilic fluorescent dye, PKH26, showed bright red 
round cells when observed with 20x magnification and fluorescence microscopy (A). Flow 
cytometry illustrates unstained PUCs control (open histogram) and PKH-26-stained PUCs (filled 
histogram) (B). Y axis represents counted cells and X axis represents red fluorescent intensity in 
log scale.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
116 
 
Figure 3.2 Flow cytometry evaluation of viable PUCs stained with PKH26. 
  
Dot-plot of PUCs stained with SYTOX® Green under the red fluorescent (x-axis) and green 
fluorescent (y-axis) channels were gated as a control of the viable-unstained PUCs. The red dot 
population represents unstained viable PUCs (A). With the same gating, a population of viable 
PKH26-labeled PUCs indicated as the red population was determined after staining with 
SYTOX® Green (B). 
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Figure 3.3 Fluorescent emission scanning of PUCs labeled with the near infrared 
fluorescent dye, CellVue
®
 NIR815 by the IVIS imaging system. 
 
Fluorescent intensity images of PUCs (2 x 10
5
 cells) loaded in a 96- well black plate after 
staining with lipophilic near infrared fluorescent (CellVue® NIR815) (3) and the stained PUCs 
(2 x 10
5
 cells) cultured in vitro for 1 week after staining (2). Unstained PUCs (control) showed 
no fluorescent emitted (1). Right bar of the figure shows high (top) and low (bottom) intensity of 
emitted fluorescent. 
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Figure 3.4 Percentage of samples with detected PUCs collected from female recipients 
given male PUCs at birth by IP transplantation and sacrifice 6 or 24 hours later. 
 
Female recipients injected intraperitoneally with male PUCs and were sacrificed after 6 hours 
(n=2) (A) and 24 hours (n=2) (B) after administration. Each bar represents the number of 
samples (n=3/tissue) that were found to be positive for SRY expression. Results are shown as the 
mean; error bars indicate standard error. 
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Figure 3.5 Percentage of samples of various organs collected 1 week after oral or IP 
transplantation to newborn female recipients for which male PUCs were detected. 
 
(A) Pre-colostral female newborn pigs (n=2) fed male PUCs were sacrificed 1 week after 
administration. Tissues (n=4) were collected from each organ to determine the presence of male 
PUCs using PCR to detect the Y-chromosome gene, SRY, (B). Newborn pig (n=2) injected 
intraperitoneally with male PUCs were sacrificed 1 week post-injection. Tissues (n=4) were 
collected from each organ to determine the presence of male PUCs using PCR to detect SRY 
expression. Results are shown as the mean; error bars indicate standard error. 
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Figure 3.6 PCR screening for the SRY gene in neonatal porcine tissues after allogeneic 
transplantation. 
  
Gels representative of samples from two pigs transplanted intraperitoneally with PUCs at birth 
(A) and 1 week (B) of age followed by tissues collection 1 week after transplantation. Size of the 
SRY and porcine-specific beta-actin genes productes are 247 and 183 bp, respectively. Right 
lane is a molecular size marker (100 base pair).  
(A) Left to right: Duodenum, Jejunum, Ileum, Cecum, Colon, Stomach, Liver, Spleen, Omen,  
Kidney, Pancreas, Mesenteric lymph node, Heart, Lung, Bone marrow, Male control, Female 
control, DNA ladder. 
(B) Left to right: Duodenum, Jejunum, Ileum, Cecum, Colon, Esophagus, Stomach, Liver, 
Spleen, Omen,  Kidney, Pancreas, Mesenteric lymph node, Heart, Lung, Bone marrow, Blood, 
Female control, Male control, DNA ladder. 
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Figure 3.7 Percentage of samples of various organs collected 1 week after IP 
transplantation to 1-day and 7-day old female recipients. 
   
1 day-old (n=2) and 1 week-old (n=2) female recipients were injected IP with male PUCs and 
were sacrificed 1 week after administration. Sample (n=4/tissue) were collected from each organ 
of 1 day-old recipients (A) and 1 week-old recipients (n=3/tissue). Presence of male PUCs was 
detected as SRY expression (B). Results are shown as the mean; error bars indicate standard 
error. 
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Figure 3.8 Percentage of samples of various organs of recipients that were collected 1 week 
after IP transplantation to 2-week and 3-week old (n=2/age) female pigs. 
    
2 week-old (n=2) and 3 week-old (n=2) female recipients were sacrificed 1 week after IP 
administration of male PUCs. Samples (n=3/organ) were collected from 2 week-old recipients 
(A) and 3 week-old recipients (B). Results are shown as the mean; error bars indicate standard 
error. 
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Figure 3.9 Confocal microscopic images illustrating intestine cryosections 1 week after 
transplantation. 
 
(A) Duodenum cryosection from a control (non-transplanted) pig (m: mucosal layer, s: 
submucosal layer and vi: villus). Cryosections from the duodenum of pigs sacrificed 1 week after 
transplantation of PKH26-labeled PUCs by IP injection (B). Duodenum (C) and jejunum (D) 
cryosections of pigs fed with PKH26 labeled PUCs before consuming colostrum. Green and red 
spots indicate cell nuclei labeled with the counterstain, Syto®-16, and PKH26-labeled PUCs. 
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Figure 3.10 Confocal microscopic images of ileal and cecal cryosections from recipients 1 
week after transplantation. 
 
Ileum cryosection of 1-week old pig transplanted with PKH26 labeled neonatal fibroblasts at 
birth (A). Cross section of cecum of 1-week old pig transplanted intraperitoneally at birth with 
PKH26 labeled PUCs (B). Non-transplanted colon (C) and colon of 1-week old pig (D) after IP 
injection of PKH26 labeled PUCs at birth. 
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Figure 3.11 Confocal microscopic images illustrating organ cryosections of control and 
transplanted pigs. 
 
(A) Spleen cryosection of non-transplanted newborn pig recipient. (B) Spleen cryosection of 
newborn pig transplanted intraperitoneally with PKH26 labeled PUCs. (C) Kidney cryosection of 
non-transplanted newborn pig recipient. (D) Kidney cryosection of newborn pig transplanted 
intraperitoneally with PKH26 labeled PUCs. 
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Figure 3.12 Confocal microscopic images of stomach cryosections of control and 
transplanted pigs. 
  
(A) Stomach cryosection of non-transplanted newborn pig recipient. (B) Stomach 
cryosection of a 1-week old pig transplanted intraperitoneally with PKH26 labeled PUCs at birth. 
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Figure 3.13 Confocal microscopic images of cultured male PUCs isolated from intestines of 
female recipients and detected using FISH analysis. 
 
Green areas show Syto®16 staining of nuclei of enzymatically isolated intestinal cells. Re-
cultured PUCs are detected with a yellow spot labeling the SRY gene on Y chromosomes; 20x 
magnification with 1.2x digital zoom (A). Colony formation of isolated allogeneic male PUCs 
was observed after re-culturing; 40x magnification with 0.6 x digital zoom (B). 
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Figure 3.14 PCR detection of the SRY gene of re-cultured cells derived from intestines of 
female recipients. 
  
Agarose gel electrophoresis showed a PCR product of the SRY gene (247 bp) of engrafted male 
PUCs re-cultured from the ileum of 2-week old female porcine recipients 1 week after 
intraperitoneal transplantation. A lower PCR product (183 bp) is the porcine-specific beta actin 
gene an internal control. The left lane is a 100 bp DNA ladder.    
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Appendix A - Transplantation experiments 
Table A.1 Number of SRY positive samples derived from organs of each newborn female 
recipient after intraperitoneal transplantation for 6 hours and 1 day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ND = Not done 
a
No. of positive samples for each recipient 
 
 
 
 
 
 
 
 
Collective tissues Time after intraperitoneal injection 
6 Hours (n=2) 1 Day (n=2) 
No. of samples evaluated/organ 3 3 
Organ Samples with detected Sry DNA 
Du - Duodenum 1,1
a 
2,2 
Je - Jejunum 1,2 2,2 
Il - Ileum 1,1 3,2 
Ce - Cecum 1,1 2,1 
Co - Colon 2,0 2,2 
St - Stomach 2,1 2.1 
Li - Liver 1,1 2,3 
Sp - Spleen 1,2 2,2 
Dia - Diaphragm 3,3 3,3 
Om - Omentum 3,3 3,3 
Ki - Kidney 0,1 1,1 
Pa - Pancreas 2,1 2,2 
ML – Mesenteric lympnodes 0,1 1,1 
He - Heart 1,1 1,2 
Lu - Lung 1.1 1,1 
BM - Bone marrow (n=2) ND ND 
Bl - Blood (n=2) ND ND 
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Table A.2 Number of SRY positive tissue samples derived from each female recipient after transplantation for 1 week. 
ND = Not done 
a
No. of positive samples for each recipient 
Collective tissues Ages of recipient female pigs at transplantation 
Newborn  1 Day old (n=2) 1 Week old (n=2) 2 Weeks ol (n=2) 3 Weeks old (n=2) 
Oral feeding 
(n=2) 
Intraperitoneal 
injection (n=2) 
Intraperitoneal 
injection 
Intraperitoneal 
injection 
Intraperitoneal 
injection 
Intraperitoneal 
injection 
No. of samples 
evaluated/organ 
4 4 4 3 3 3 
Organ Samples with detected Sry DNA 
Duodenum 4,4
a 
4,4 4,4 3,2 2,3 3,3 
Jejunum 4,3 3,3 4,2 3,2 2,3 3,3 
Ileum 4,4 2,4 3,4 3,3 3,3 3,3 
Cecum 3,4 4,3 2,4 2,3 3,2 3,3 
Colon 3,3 2,4 3,3 2,3 3,3 3,3 
Esophagus 4,3 ND ND ND ND ND 
St - Stomach 4,3 4,4 4,3 3,2 3,3 3,2 
Li - Liver 3,4 3,3 4,2 2,3 2,3 2,2 
Sp - Spleen 2,4 4,4 4,4 2,3 3,2 2,2 
Om - Omentum 4,4 4,4 3,4 3,3 2,3 2,2 
Ki - Kidney 2,1 2,3 2,2 2,2 2,2 2,1 
Pa - Pancreas 3,3 3,4 3,4 2,3 3,2 3,2 
ML – Mesenteric lymph 
nodes 
3,3 2,2 2.2 2,1 1,2 2,2 
He - Heart 1,3 3,2 3,2 2,2 3,1 2,2 
Lu - Lung 2,2 2,3 2,3 2,2 2,2 2,2 
Ut - Horn of uterus ND ND ND ND 2,2 2,2 
Ub - Urinary bladder ND ND ND ND 1,3 1,3 
Mu - Muscle 
(Semimembranosus) 
ND ND ND ND ND 2,2 
BM - Bone marrow 2,2 3,2 2,4 2,3 2,2 2,2 
Bl - Blood 
 
0 0 0 0 0 0 
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 Table A.3 Number of re-cultured cell samples isolated from small intestines of female porcine recipients positive to SRY gene  
after transplantation for 1 week. 
Cont = Microbial contamination 
ND = Not done 
a
No. of positive samples for each recipient 
 
 
 
 
 
 
 
 
 
 
Detection methods Ages of recipient female pigs at transplantation 
Newborn (n=2) 1 Day old (n=2) 1 Week old (n=2) 2 Week old (n=2) 3 Week old (n=2) 
Oral feeding 
Intraperitoneal 
injection 
Intraperitoneal 
injection 
Intraperitoneal 
injection 
Intraperitoneal 
injection 
Intraperitoneal 
injection 
Samples with detected Sry DNA 
PCR 1,1
a 
1,1 1,1 1,1 1,1 1,1 
Samples with detected Sry probes 
3,3 
4,2 
3,2 
2,3 
3,3 
Fluorescent in situ 
hybridization (FISH) 1,1 1,1 ND 1,Cont 1,1 1,1 
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Table A.4 Details of the transplantation experiments
a
 
Transplantation 
/recipient 
Pig 
number 
Dye/donor 
cells 
Collected tissues performed by detection 
methods 
Detection methods 
Transplantation 
time 
Collected 
Tissues/  
organ 
Oral/pre-
nursed 
newborn pig 
N=2 PKH26/PUCs Organs/Blood CM/FC 1 week N=4 
N=2 NIR815/PUCs Organs, Blood, BM/Intestine PCR/(PCR&FISH)  N=4 
Oral/nursed 
newborn pig 
N=2 PKH26/PUCs Organs/blood CM/FC 1 week N=4 
IP/newborn pig 
 
N=2 PKH26/PUCs Organs/blood CM/FC 1 week N=4 
N=2 NIR815/PUCs Organs, Blood, BM/Intestine PCR/(PCR&FISH) 1 week N=4 
IP/newborn pig N=2 PKH26/ FIBs Organs/Blood CM/FC 1 week N=4 
IP/newborn pig N=2 PKH26/PUCs Organs/Blood PCR/FC 6hr N=3 
IP/newborn pig N=2 PKH26/PUCs Organs/Blood PCR/FC 24hr N=3 
IP/1-day pig N=2 PKH26/PUCs Organ,BM,Blood/Blood/Organs/intestine PCR/FC/CM/PCR 1 week N=4 
IP/1week pig N=2 NIR815/PUCs Organs, Blood, BM/Intestine PCR/PCR&FISH 1 week N=3 
IP/2week pig N=2 NIR815/PUCs Organs, Blood, BM/Intestine PCR/PCR&FISH 1 week N=3 
IP/3week pig N=2 NIR815/PUCs Organs, Blood, BM/Intestine PCR/PCR&FISH 1 week N=3 
a
Abbreviation: BM: Bone marrow, CM: Confocal microscopy, FC: Flow cytometry, FISH: Fluorescent in situ hybridization 
 
